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Improving the expression level of recombinant mammalian proteins has been 
pursued for production of commercial biotherapeutics in industry, as well as for 
biomedical studies in academia, as an adequate supply of correctly folded proteins is a 
prerequisite for all structure and function studies. Presented in this dissertation are 
different strategies to improve protein functional expression level, especially for 
membrane proteins. The model protein is neurotensin receptor 1 (NTSR1), a hard-to-
express G protein-coupled receptor (GPCR). GPCRs are integral membrane proteins 
playing a central role in cell signaling and are targets for most of the medicines sold 
worldwide. Obtaining adequate functional GPCRs has been a bottleneck in their structure 
studies because the expression of these proteins from mammalian cells is very low. 
The first strategy is the adoption of mammalian inducible expression system. A 
stable and inducible T-REx-293 cell line overexpressing an engineered rat NTSR1 was 
constructed. 2.5 million Functional copies of NTSR1 per cell were detected on plasma 
membrane, which is 167 fold improvement comparing to NTSR1 constitutive expression. 
The second strategy is production process development including suspension 
culture adaptation and induction parameter optimization.  A further 3.5 fold improvement 
was achieved and approximately 1 milligram of purified functional NTSR1 per liter 
suspension culture was obtained. This was comparable yield to the transient baculovirus-
insect cell system. 
The third strategy is high throughput miRNA screening. MiRNAs are a novel 




NTSR1-expressing cell line was subjected to human miRNA mimic library screening and 
nine miRNA mimics were identified to improve functional expression of NTSR1 by as 
much as 48%. Interestingly, five out of nine identified miRNA mimics were effective in 
improving the functional expression of other proteins, including luciferase (cytosolic 
protein), serotonin transporter (membrane protein) and glypican-3 hFc protein (secreted 
protein). These indicated that the identified miRNAs could have a wide role in enhancing 
production of proteins with biomedical interest. 
As genome-wide siRNA screens has emerged to be a powerful methodology for 
deducing gene functions in various diseases, we applied this technology on HEK293 cells 
constitutively expressing luciferase reporter to generate a genome-wide profile for 
recombinant protein expression process. Up to 362 genes associated with significantly 
enhanced luciferase expression were discovered and 28 of them were found to be 
enriched in splicesome pathway. Moreover, top 10 genes leading to greatest improvement 
of luciferase production were validated and tested with secreted and membrane proteins.  
Investigation of these genes/pathways may provide profound information to 
understanding protein biosynthesis process in mammalian cells. Oaz1 gene for example, 
was chosen for further investigation. Oaz1 encodes ornithine decarboxylase (ODC) 
antizyme 1, a major negative regulator of ODC and cellular polyamines. In our study, it is 
found that when antizyme was depleted, ODC enzyme and cellular polyamines levels 
were up-regulated, leading to enhanced luciferase translation.   







It has long been pursued by pharmaceutical and biotechnology industry to 
enhance the quality and quantity of recombinant proteins produced from host cells by 
traditional (e.g. media and bioprocess conditions optimization) and cell engineering 
approaches. In academia, the expression of recombinant proteins in general and 
mammalian proteins in particular, is also at the heart of current medical and structural 
studies.  
This dissertation consists of six chapters and is mainly focused on the 
improvement of functional expression of a hard-to-express membrane protein- 
neurotensin receptor (NTSR1).  
Chapter 1 provides a review on the ongoing effort to target bottlenecks along 
transcription, translation, protein processing and secretion pathways, as well as cell 
growth and survival to improve expression of low yielding proteins in a variety of hosts 
including bacterial, fungal, insect, and mammalian cells. The contents of Chapter 1 have 
been published in the Current Opinion in Structural Biology journal. Permission for its 
use was granted by the publisher, Elsvier (license number 3606050366032).  
Chapter 2 describes the construction of a stable HEK293 cell line with high-level 
functional NTSR1 expression and a quantitative comparison with NTSR1 produced from 
insect cells. The text and illustrations used in Chapter 2 have been published in the PLOS 
ONE journal and Methods in Molecular Biology journal. Permission was granted by 




Chapter 3 features the identification of five microRNAs (hsa-miR-22-3p, hsa-
miR-22-5p, hsa-miR-18a-5p, hsa-miR-429 and hsa-miR-2110) that can further improve 
NTSR1 functional expression in HEK293 cells. Their wider application was 
demonstrated by expression enhancement of other cytosolic, secreted and membrane 
proteins. The contents of Chapter 3 have been published in the Biotechnology and 
Bioengineering journal. Permission for its reuse was granted by John Wiley and Sons 
(license number 3606050872125).  
Chapter 4 extends the scope to system biology of HEK293 cells and identified 10 
significant influential genes for heterologous protein production by genome-wide loss-of-
function studies.   
Chapter 5 focuses on one of the identified top 10 genes (oaz1) and investigated 
the mechanism of improved protein expression upon oaz1 gene knockdown. A 
manuscript is being prepared based on contents of chapter 4 and 5.  
Finally, Chapter 6 concludes this dissertation and suggests the future work to 
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Chapter 1: Engineering cells to improve recombinant protein expression 
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1.1 - Summary 
 Improving the expression level of recombinant mammalian proteins has not only 
been pursued by biotechnologist for production of commercial biotherapeutics, but has 
also been at the heart of numerous biomedical studies in academia, as an adequate supply 
of correctly folded proteins is a prerequisite for all structure and function studies. In 
industry, there have been consistent efforts made towards process development for 
recombinant protein therapeutics production, especially on culture medium optimization 
and feeding strategies. In addition, significant progress has been achieved for the past 
decades in engineering and development of new cell lines to improve recombinant 
protein production for structural, biochemical, and commercial applications.  
This chapter is a review on recent advances of improving recombinant protein 
production by engineering a variety of expression host including bacteria, fungi, insect 




engineering strategies were developed targeting bottlenecks in transcription, translation, 
protein processing and secretory pathways, as well as cell growth and survival. A 
combination of metabolic engineering and synthetic biology has been used to improve the 
properties of cells for protein production, which has resulted in enhanced yields of 
multiple protein classes.  
 
1. 2 - Introduction  
With hundreds of billion dollar global market[1] and 10-20% annual increases in 
revenue worldwide[2], protein-based therapeutics have received unprecedented 
recognition of success and great potential. Since the production of the first approved 
recombinant protein (insulin) in the early 1980s, there have been continuous efforts to 
improve recombinant protein productivity and quality, especially for monoclonal 
antibodies (mABs), which accounts for approximately half of the sales[1]. Process 
development is very effective to improve productivity, especially the optimization of 
culture medium and feeding strategy. In industry, up to 10 grams of mAB or Fc fusion 
proteins can be produced in optimized fed-batch process with chemically-defined 
media[3]. In parallel, cell line engineering and development is also vital for cell-based 
production process. Development of cell lines with improved stability and protein 
productivity, quality, and biosimilarity has been pursued for decades.  
Expression of recombinant mammalian proteins is also at the heart of medical and 




available for many hosts [4-6], and significant progress has been achieved to produce 
thousands of recombinant proteins for structural and biochemical studies, it has been 
challenging to produce many difficult proteins, such as membrane proteins, large protein 
complexes and post-translationally modified proteins [7, 8]. 
A critical area is mammalian integral membrane proteins such as receptors, ion 
channels and transporters which are encoded by 20-40% of all open reading frames 
(ORFs) in the mammalian genome[9] and are targets of most of the medicines sold 
worldwide[10]. Even though more than 100,000 structures have been deposited in Protein 
Data bank, the overexpression of membrane protein remains difficult [8, 11] and only 952 
membrane protein structures are available as of April, 2015 
(http://blanco.biomol.uci.edu/mpstruc/). Rational attempts to improve membrane protein 
expression may not lead to expected results as membrane proteins involve particularly 
complex folding, assembly, and processing pathways, and there is only limited 
information for the bottlenecks that may reside in the protein production steps, such as 
transcription, translation, protein folding, secretion and cell viability. 
This chapter will summarize the most recent successful cases where the protein 
productivity was improved through different cellular engineering strategies. Presented 
here are a variety of host cells, e.g. bacteria, fungi, insect cells and mammalian cells. 
Different protein types are all included, e.g. secreted, cytosolic and hard-to-express 
membrane proteins. Cellular engineering strategies reviewed in this chapter were 
categorized by the biological process engineered, including transcription, translation, 




1.3 - Choice of host cell line 
 The first step in any strategy to over-produce proteins is the selection of the 
expression host. Table 1.1 includes 11 biopharmaceutical products selected from GEN’s 
top 25 best-selling drug list from 2013. Seven out of eleven products were produced from 
mammalian expression system (mostly from Chinese Hamster Ovary cells) and the 
annual revenue generated using mammalian system took up 74% of overall revenue from 
the 11 top-selling biopharmaceutical products. 
However in academia, especially in crystallography studies, mammalian cells are 
not widely used. According to statistics from the Protein Data Bank 
(http://www.rcsb.org) and the ‘Membrane Proteins of Known Structure Database’ 
(http://blanco.biomol.uci.edu/mpstruc/), of all the proteins that had their structures 
determined between 2004 and 2014, 78% were expressed in Escherichia coli and only 
1.8% in mammalian cells (Fig.1.1A). For the overexpression of membrane proteins, E. 
coli was utilized on average less (61%) and eukaryotic expression systems were used 
comparatively more (Fig. 1.1B). Notably, there is an increasing trend in the use of more 
complex eukaryotic hosts (insect and mammalian cells, Fig. 1.1C), which reflects an 
increase in the number of mammalian membrane proteins being crystallized, particularly 
G protein-coupled receptors (GPCRs) [12]. 
 
1.4 -  cell engineering strategies 




One of the most important choices in planning a strategy for overexpression of 
proteins is the type of promoter to use, and it is often the case that the strongest promoter 
will be the best for producing large amounts of correctly folded protein. Thus the most 
commonly used promoters are the T7 promoter in E. coli, the polyhedrin promoter in the 
baculovirus expression system and the Cytomegalovirus (CMV) promoter in mammalian 
cells. If transcription is the rate limiting step in protein production, even after choosing a 
strong promoter, then increasing further the strength of the promoter may be effective. 
For example, Quilici et al. constructed a strong CMV promoter variant through 
introducing a 200-nucleotide deletion of intron A that increased luciferase expression up 
to 2 fold in mammalian cells [13]. However, recent studies have shown that increasing 
the amount of mRNA encoding the protein of interest does not necessarily lead to 
improved protein production in E.coli[14] or insect cells [15]. In these instances, it is 
possible that the rate limiting step is protein folding, perhaps due to limitations in host 
cell factors, such as molecular chaperones. Enhancements in protein expression can be 
achieved through reducing the rate of transcription, either by substituting a strong 
promoter with a weaker one [14, 15], or by weakening a strong promoter by introducing a 
point mutation[16]. An alternative approach is to reduce the levels of polymerase in the 
host cell. For example, the levels of the T7 DNA polymerase expressed in E. coli can be 
modulated by altering the expression levels of the natural inhibitor T7 lysozyme, which is 
under the control of a tightly regulated inducible promoter, hence fine-tuning the rates of 
transcription. Wagner et al. improved expression of 14 membrane proteins using this 




Even when strong promoters are used, host cell factors can result in low rates of 
transcription. For example, during the construction of stable mammalian cell lines with 
the gene of interest expressed from the CMV promoter, poor expression could result from 
epigenetic silencing of the promoter. This can be alleviated by engineering the nuclear 
matrix attachment region (MAR) [18] or by combining a MAR with a mammalian 
replication initiation region (IR) [19, 20], consequently improving recombinant protein 
production in mammalian cell lines. 
1.4.2 Enhancing translation 
Translation of the gene of interest may also be inhibited by host cell silencing 
processes during protein production. For example, eukaryotic translation initiation factor 
2(eIF2) may become phosphorylated after DNA plasmid transfection or upon virus 
transduction, which will inhibit translation and thus decrease protein expression. 
However, viruses have evolved mechanisms to circumvent this. Gantke et al. co-
expressed the Ebola virus protein 35, which is a viral protein that prevents translational 
silencing, and increased recombinant protein production by 10-fold [21]. An alternative 
approach to circumvent translational silencing in insect cells following baculovirus 
infection is to co-express eIF4E, which resulted in a 2-fold increase in the production of a 
secreted alkaline phosphatase (SEAP)-EGFP fusion protein (SEFP)[22].  
1.4.3 Folding and secretory pathway engineering 
Molecular chaperones have been applied to improve protein production in various 




and prevent aggregation [23]. The most extensively used chaperone systems that have 
facilitated protein production in E.coli are DnaK-DnaJ-GrpE and GroEL-GroES[24, 25]. 
In insect cells, host protein biosynthesis shuts down as a result of infection by the 
recombinant baculovirus, which can adversely affect levels of molecular chaperones 
important for the folding of secreted proteins and membrane proteins in the endoplasmic 
reticulum (ER), particularly in relation to the high levels of protein synthesis resulting 
from high mRNA levels produced from the polyhedrin promoter. Hence, co-expression 
of the membrane-bound molecular chaperone calnexin enhanced the expression of 
functional serotonin transporter (SERT) by nearly 3 fold [26], and co-expression of the 
soluble molecular chaperone calreticulin increased secretion of SEAP-EGFP fusion 
protein in insect cells [22]. Whether a lack of appropriate molecular chaperones in 
heterologous systems contributes to low levels of functional protein sometimes is 
difficult to assess. However, overproduction of mammalian calnexin in the yeast 
Hansenula polymorpha did increase production of the truncated glycoprotein of rabies 
virus[27], suggesting that at least in this case the folding environment in the yeast ER was 
not optimal for folding large amounts of glycoprotein. 
However, co-expression of molecular chaperones is not a panacea and does not 
often give a 10-fold or more improvement in expression levels. Part of the problem is that 
overexpression of ER resident chaperones such as calreticulin might burden the ER and 
activate an unfolded protein response [22]. Another more challenging issue is that 
molecular chaperones may act in a concerted fashion to promote protein folding in a 
poorly understood process, suggesting that it may be best to overexpress multiple 




to prevent overwhelming the cells protein production resource and also the stoichiometry 
between chaperones will have to be regulated. Another problem associated with 
engineering the chaperone and secretory pathway is that it can be protein and host 
specific. For example, co-expression of protein disulfide isomerase increased yields of 
albumin fusion proteins in the yeast Pichia pastoris[28] but did not improve functional 
SERT expression in insect cells [26]. Similarly, SRP 14 overexpression led to a 
substantial improvement of IgG production in CHO cells, but the strategy was ineffective 
in human cell lines producing alkaline phosphatase [29, 30].  
An alternative strategy to overexpressing molecular chaperones is to delete 
endogenous competing chaperones in order to channel the nascent peptide chain to the 
desired signal recognition particle (SRP) secretory pathway. Indeed, Nannenga et al. 
showed that membrane protein insertion in E. coli improved and expression levels 
increased through eliminating competition between trigger factor (TF) and the SRP for 
the nascent polypeptide chain [16, 31]. 
Another strategy to improve secretion is to improve vesicular trafficking from the 
ER to the cell surface. Co-expression of secretory proteins which modulate vesicle 
trafficking, such as soluble NSF receptor (SNARE) proteins (SNAP-23 or VAMP8), 
improved production of SEAP and monoclonal antibodies by 2-3 fold in mammalian 
CHO-K1 cells [32]. Likewise, overexpression of SNARE-interacting Sec1p and Sly1p 
proteins improved expression of α-amylase and human insulin precursor in 




improved production of tissue-plasminogen activator (t-PA) [34], human serum albumin 
(HSA) and monoclonal antibodies in CHO [35]. 
1.4.4 Protein sequence mutagenesis  
Mutating the sequence of the protein target can also improve expression levels of 
the target protein. Sometimes this may be achieved through rational approaches such as 
analyzing the structure of the protein, as in the D500G mutation of laccase in E.coli [36] 
and the cysteine mutation of coagulation factor VIII [37]. However, in many instances 
there is insufficient evidence to suggest why a protein does not overexpress, so high-
throughput mutagenic strategies can be used. For example, directed evolution coupled 
with random mutagenesis, followed by screening and selection was used by Sarkar et al. 
to evolve a GPCR, the rat neurotensin receptor type I (NTSR1) in E. coli. A mutant with 
14 nucleotide substitutions retained the biochemical properties of the wild type receptor 
together with a 10-fold increase in functional expression and slightly increased 
thermostability [38]. Similarly, Heggeset et al. applied combinatorial mutagenesis and 
selection based on ampicillin tolerance in E.coli to evolve the signal sequence of β-
lactamase and improved SEAP production up to 8-fold [39]. 
In theory, a more elegant and simple strategy would be to use in vivo mutagenesis 
coupled to screening or selection to improve expression. This approach was used by 
Majors et al. to evolve an anti-apoptotic gene Bcl-xL in a mammalian expression system 
by harnessing the somatic hypermutation capability of human Ramos B-cell line. The 




subjected to rounds of staurosporine treatment to identify mutants with reduced apoptosis 
activation and higher YFP-Bcl-xL expression levels [40]. 
1.4.5 Cell proliferation and survival engineering  
The delay or prevention of the apoptosis cascade activation has been successful in 
preventing cell death and improving protein production in CHO cells under stress 
conditions [41].  Co-expression of the anti-apoptotic protein Bcl-xL in CHO cells 
improved the expression of epidermal growth factor receptor, fibroblast growth factor 
receptor 3 and receptor tyrosine kinases proteins [42]. Knock-out of the genes encoding 
the pro-apoptotic factors Bax and Bak in a CHO-K1 cell line improved cell viability, 
reduced levels of transfection-induced apoptosis and led to up to 4 fold higher antibody 
titers [43]. Similarly, stable inhibition of the pro-apoptotic microRNA mmu-miR-466h-
5p in CHO cells delayed the onset of apoptosis, increased the maximum viable cell 
density and enhanced expression of SEAP [44]. 
Enhanced cell proliferation represents another potential approach to increase 
biomass and obtain higher volumetric yield during large scale production processes. For 
example, a metabolically engineered respiratory strain of S. cerevisiae (TM6*) doubled 
volumetric yield of Fps1 and at least quadrupled the yield of two human GPCRs (A2aR 
and CNR2)[45]. Overexpression of the mammalian target of rapamycin (mTOR) 
simultaneously improved cell growth, proliferation, viability and specific productivity of 
antibody, SEAP and secreted α-amylase in CHO cells [46]. Similarly, overexpression of 
miR-7 in CHO cells enhanced cell proliferation, leading to higher Epo-Fc titer [47]. 




demonstrated by chemical inhibition of autophagy in CHO cells, which led to decreased 
cell concentration but a 2.8 fold increase in t-PA [48]. 
1.4.6 Other strategies: 
In cases where the heterologous proteins are toxic to the host cells, the presence 
of inhibitors can protect the host by sequestering proteins and keeping them in an inactive 
state. For example, co-expression of lysozyme together with its inhibitor Ivy, repressed 
lysozyme lytic activity in cytoplasm, and, along with transcription enhancement and 
chaperone co-expression, remarkably improved soluble lysozyme production in 
E.coli[49]. 
 
1.4 - Conclusion 
Recombinant protein expression has facilitated biochemical and structural studies 
of thousands of naturally low abundance proteins. Methodologies that improve 
expression levels can be particularly advantageous for many difficult-to-produce proteins 
or if the protein is being produced for therapeutic or industrial purposes. To improve 
expression levels further through cell engineering requires an understanding of both the 
host organism and the biology of protein expression. In this chapter, we reviewed some 
recent successful cases that target potential bottlenecks in protein production, using 
strategies focused on optimizing transcription, translation, engineering the folding and 
secretory pathways, mutating the target protein sequence, and enhancing cell proliferation 




strains, and now there is an expanding effort to engineer insect and mammalian hosts 
such as HEK293 and CHO cell lines[50, 51], especially for functional expression of 
mammalian membrane proteins that include particularly complex folding, assembly, and 
processing pathways [52-54].However, in many instances there is only limited 
information on the factors that affect expression of any particular protein, so current 
strategies are often piecemeal and focus on only one or two aspects of the protein 
production process. A goal for the future is to identify limiting bottlenecks in the protein 
expression process such as transcription, translation, protein folding, secretion and cell 
viability and construct robust cell factories through a holistic approach that considers all 
the bottlenecks and engineer these through an integrative process to enable high-level 







Figures and tables 
Fig.1.1. Summary of host cell line usage for production of recombinant proteins in 
structural studies between 2004 and 2014.  (A) Break down of leading host cell choices 
for the expression of all types of proteins (B) Break down of leading expression 
organisms for integral membrane protein production. (C) Increasing application of higher 








Table.1.1 Top selling biopharmaceutical products in 2013 (EU and US market) 
Rank Product Revenue 
US $ (billion) 
Manufacturer Type of molecule Expression 
 system 
Indication  
1 Humira 10.66 Abb Vie  Human Mab mammalian Rheumatoid arthritis 
2 Remicade 8.94 Johnson &Johnson 
and Merck& Co 
Chimeric Mab mammalian Rheumatoid arthritis 
3 Rituxan 8.92 Roche (Genentech) 
and Biogen Idec  
Chimeric Mab mammalian Rheumatoid arthritis 
5 Enbrel 8.33 Amgen and Pfizer Mab fusion protein mammalian Rheumatoid arthritis 
6 Lantus 7.85 Sanofi Modified insulin E.coli Diabetes 
7 Avastin 7.04 Roche Humanized Mab mammalian cancer 
8 Herceptin 6.84 Roche Humanized Mab Mammalian Breast cancer 
14 Neulasta 4.39 Amgen PEGylated GCSF E.coli Neutropenia 
18 Prevnar 3.97 Pfizer Streptococcus 
pneumonia 
vaccine conjugate 










Table.1.2. Improvements in Protein Expression Levels for Different Cell Engineering Strategies 
Protein Location Expression host Fold increase in 
protein production 
Reference 
Strategy 1: optimizing transcription and enhancing translation 
Luciferase intracellular CHO-K1, HepG2, HEK-293, 
COS-7 
3 [13] 
D-amino acid oxidase 
Glutaryl-7-aminocephalosporanic acid acylase 













Secreted alkaline phosphatase extracellular Insect cells significant [15] 
Deltarhodopsin  



















































SEAP- EGFP fusion protein  extracellular Insect cells 2 [22] 
Strategy 2:  Folding and secretory pathway engineering 
Secretory alkaline phosphatase- EGFP fusion 
protein  
extracellular Insect cells 2 [22] 
Human papillomavirus 16 E7 oncoprotein fused 
to C-terminus of Tobacco mosaic virus coat 
protein 
intracellular E.coli n.r. [24] 
Aldehyde dehydrogenase 3A1  intracellular E.coli 4.9 [25] 
Serotonin transporter membrane Insect cells 3 [26] 
Glycoprotein of rabies virus (truncated) extracellular H. polymorpha n.r. [27] 
ZraS  
Deltarhodopsin  

















































Interleukin-1 receptor antagonist – HSA  









Antibody  extracellular CHO 4-7 [29] 
Strategy 3:  Protein sequence mutagenesis   
Benzenediol- oxygen oxidoreductase intracellular E.coli 3.14 [36] 






Neurotensin receptor membrane E.coli 10 [38] 
Signal sequence of β-lactamase intracellular E.coli 5.5 [39] 












Epidermal growth factor receptor 
Fibroblast growth factor receptor 3 













Antibody extracellular CHO-K1 4 [43] 
Secreted alkaline phosphatase  extracellular CHO 1.43 [44] 
Glycerol transport facilitator Fps1 
A2a adenosine receptor  




























Epo-Fc  extracellular CHO n.r. [47] 
 
Other strategies 




Chapter 2: Stable expression of the neurotensin receptor NTSR1 with T-REx-293 
cells and comparison with baculovirus- insect cell system 
 
Abbreviations used: 
GPCR, G protein-coupled receptor; NTSR1, neurotensin receptor type 1; NT: 
neurotensin; HEK, human embryonic kidney; CHO, Chinese hamster ovary; tetO2, 
tandem tet operator; TetR, tet repressor protein; GnTI, N-acetylglucosamine transferase I; 
DMEM, Dulbecco’s modified Eagle’s medium; PBS, phosphate-buffered saline; FBS, 
fetal bovine serum; DM, n-Decyl-β-D-maltopyranoside; DDM, n-dodecyl--D-
maltopyranoside; CHS, cholesteryl hemisuccinate Tris salt; CHAPS, 3-[(3-
cholamidopyropyl) dimethylammonio] -1- propanesulfonate; NaBu, sodium butyrate; 
CMV, cytomegalusvirus; MOI, multiplicity of infection;  
 
2.1 - Summary  
G protein-coupled receptors (GPCRs) are associated with a wide array of diseases 
and are targets of most of the medicines sold worldwide. Despite their clinical 
importance, only 62 unique GPCR structures have been determined as of December 
2014. The first step for structural studies is to establish the expression of correctly folded, 
functional receptors in recombinant host cells at quantities to allow subsequent 
purification and crystallization trials. Baculovirus- insect cell and tetracycline- inducible 
mammalian cell lines (T-REx-293) are intensively used for GPCR production. Here a 
stable and inducible T-REx-293 cell line overexpressing an engineered rat neurotensin 




culture adaptation and induction parameter optimization, approximately 1 milligram of 
purified functional NTSR1 per liter suspension culture was obtained. This stable 
inducible mammalian expression system was also quantitatively compared with the 
transient baculovirus-insect cell system throughout a milligram-scale expression and 
purification process. The two systems were comparable on aspects of functional NTSR1 
expression level and receptor binding affinity for ligand [
3
H]NT. However, NTSR1 
surface display on T-REx-293 cells determined by radio-ligand binding assays was 2.5 
fold higher than that on insect cells. This work demonstrates two approaches for 
preparing milligram-scale quantities of NTSR1 purified enough for structural studies and 
provides useful input to users in choosing and optimizing an appropriate expression host 
for other GPCRs. 
 
2.2 - Introduction   
As was discussed in Chapter 1, there have been numerous efforts in improving the 
expression level of recombinant proteins for production of commercial biotherapeutics as 
well as for biomedical studies in academia. A critical and difficult area is the expression 
of mammalian integral membrane proteins such as receptors, ion channels and 
transporters. GPCRs are a superfamily of integral membrane proteins that have seven 
transmebrane domains. They play a central role in cell signaling by transmitting 
extracellular chemical signals across membranes to intracellular effector pathways. 
Closely associated with a wide array of physiological diseases, these proteins  are targets 
of most of the medicines sold worldwide [10]. As of December 2014, structures of 62 




Crystallographic studies of GPCRs are very rewarding because they provide insight into 
mechanistic aspects of cell signaling at high resolution, thus opening the pathway to 
ultimately improve drugs and medicines targeting a wide variety of diseases[10]. In the 
past few years, we started to see an explosion in the field of GPCR structure 
determination. This exciting progress is based on a tremendous amount of methods 
development, such as advances in crystallization methods, the development and 
implementation of the concept of conformational thermostabilization of GPCRs, and the 
development of microfocus x-ray synchrotron technologies[55]. Yet, the supply of ample 
amounts of correctly folded receptors is the key prerequisite for successful structural 
studies. 
The goal of this research is to improve expression level of functional neurotensin 
receptor type 1 (NTSR1), a difficult-to-express GPCR. It’s agonist is neurotensin (NT), a 
13 amino acid residue peptide that is found in the nervous system and in peripheral 
tissues [56]. NT displays a wide range of biological activities and plays important roles in 
Parkinson’s disease, in pathogenesis of schizophrenia, in modulation of dopamine 
neurotransmission, hypothermia, antinociception and in promoting the growth of cancer 
cells [57-61]. Three neurotensin receptors have been identified. NTSR1 and NTSR2 
belong to the class A GPCR family, whereas NTSR3 is a member of the sortilin family 
with a single transmembrane domain [62-64]. Most of the known effects of NT are 
mediated through NTSR1[60]. 
Wild-type rat NTSR1 has previously been expressed in Escherichia coli fused 
with maltose-binding protein (MBP), and large-scale purification has been accomplished 




coli as the expression host to identify stabilized NTSR1 mutants suitable for 
crystallization [66, 67]. The structure of stabilized NTSR1 mutant (GW5) with T4 
lysozyme replacing most of the third intracellular loop, was determined with receptors 
transiently expressed in baculovirus-insect cell system in 2012 [67].  
In this work, mammalian cell line HEK293 was chosen as the expression host 
despite it’s not a popular choice for structural studies[7], likely as the result of  the high 
cost associated with serum needed for cell culture and the lengthy process of stable cell 
line construction. However, mammalian cells are ideally suited for efficient expression of 
functional membrane proteins because of the near-native environment they provide, such 
as N-glycosylation, a machinery for post-translational modification, molecular 
chaperones, and a suitable lipid environment [7]. In addition, the continuous production 
capability is yet another advantage which the baculovirus-insect cell system cannot 
provide.  
As constitutive mammalian expression systems sometimes fail to provide 
adequate amounts of membrane proteins for structural studies, a tetracycline-inducible 
expression system [68] was demonstrated to be advantageous for high-level expression of 
GPCRs in functional form [50-52]. In tetracycline-free medium, mammalian cells are 
allowed to reach high cell density without the stress from leaky GPCR expression; after 
addition of tetracycline and thus GPCR production for typically 24 –72 hrs, cells are 
harvested. 
The tetracycline-inducible expression system developed for recombinant 
mammalian cell expression hosts contains two components of the tetracycline-resistance 




which is positioned upstream of the gene of interest; and the Tet repressor protein 
(TetR)[70].  In the absence of tetracycline, the TetR homodimer binds with high affinity 
to the tetO2 sequence downstream of the TATA element of the human cytomegalusvirus 
(CMV) major immediate-early promoter, thus blocking transcription of the gene of 
interest (Fig.2.1A). Upon addition of tetracycline, TetR abolishes its association with 
tetO2, allowing transcription of the gene of interest under the control of the strong CMV 
promoter [70] (Fig.2.1B). 
This system, developed by Yao et al.[68], has been commercialized as the T-REx 
system (Life Technologies) and several tetracycline-inducible mammalian cell lines 
(HEK293, CHO, Hela, etc.) are now available. Those cell lines have been stably 
transfected with the pcDNA6/TR regulatory vector which leads to high level, constitutive 
expression of TetR [70]. The gene of interest is cloned into pcDNA™4/TO (or an 
equivalent plasmid), which contains the complete CMV enhancer-promoter sequence, 
with the tetO2 operator region starting 10 nucleotides downstream of the last nucleotide 
of the TATA element [68]. 
The successful application of the tetracycline-inducible system for GPCR 
expression was first demonstrated by Reeves et al. [51]. A tetracycline-inducible and 
suspension adaptable HEK293S-TetR cell line successfully overproduced milligram 
quantities of opsin mutants per liter of culture in bioreactors. Meanwhile, a HEK293S-
GnTI
-
-TetR cell line, which lacks the N-acetylglucosaminetransferase I (GnTI) enzyme, 
was developed and gained increasing popularity for membrane protein production for 
structural studies [52-54], owing to the homogeneously N-glycosylated proteins produced 




Here we report the expression of NTSR1-GW5-i3 in a stable, inducible T-REx-
293 cell line and in baculovirus infected insect cells. NTSR1-GW5-i3 has six stabilizing 
mutations[67], truncated N- and C-termini, and parts of the third intracellular loop 
deleted. We provide a quantitative comparison between the two production hosts 
regarding aspects of functional NTSR1-GW5-i3 expression levels and receptor yield 
after purification, as well as binding properties and cell surface display of the receptors. 
The scale-up of NTSR1-GW5-i3 production using T-REx-293 suspension cultures in a 
bioreactor allows the continued production of the receptor suitable for the application of 
biophysical analyses such as Nuclear magnetic resonance (NMR) spectroscopy. 
 
2.3 - Materials and Methods  
2.3.1. Materials 
The tritiated agonist [
3
H]NT ([3,11-tyrosyl-3,5-3H(N)]-pyroGlu-Leu-Tyr-Glu-
Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu) was purchased from Perkin Elmer. Unlabeled 
NT was synthesized by the Center for Biologics Evaluation and Research (Food and 
Drug Administration). The detergents n-dodecyl--D-maltopyranoside (DDM), 3-[(3-
cholamidopyropyl) dimethylammonio] -1- propanesulfonate (CHAPS) and cholesteryl 
hemisuccinate Tris salt (CHS) were obtained from Anatrace. 
2.3.2. The NTSR1 construct used for expression in insect cells and T-REx-293 cells 
The construct NTSR1-GW5-i3 consisted of the hemagglutinin signal peptide 
and the Flag tag [71], followed by the stabilized rat neurotensin receptor NTSR1 (T43-




intracellular loop 3 residues G275-E296 deleted [67]. A deca-histidine tag was present at 
the C-terminus. We refer to this construct in the following as NTSR1. For expression 
using the baculovirus-insect cell system, NTSR1 was subcloned into the transfer vector 
pFastBac1 (Invitrogen) thus placing NTSR1 under the control of the strong polyhedrin 
promoter. For stable expression in T-REx-293 cells, NTSR1 was subcloned into the 
plasmid pACMV-tetO (a kind gift from Dr. Philip J. Reeves) downstream of the 
tetracycline-controlled CMV promoter [51] (Fig.2.2). 
2.3.3. Transient expression of NTSR1 in the baculovirus-insect cell system 
Recombinant baculoviruses were generated using the pFastBac1 transfer plasmid 
system (Invitrogen). Trichoplusia ni cells were infected at a cell density of 0.8-1 million 
cells/ml with recombinant virus at a multiplicity of infection (MOI) of 5, and the 
temperature was lowered from 28C to 21C. Cells were harvested by centrifugation 48 
hours post infection, resuspended in hypotonic buffer (10 mM Hepes pH 7.5, 10 mM 
MgCl2, 20 mM KCl), flash-frozen in liquid nitrogen and stored at –80C until use. 
2.3.4. Stable expression of NTSR1 in the T-REx-293 system 
The T-REx-293 cell line was maintained as an adherent culture in DMEM 
containing 10% certified FBS and 5 µg/ml blasticidin (Invitrogen). The cells were 
transfected with the plasmid pACMV-tetO-NTSR1 (Fig.2.2). using Lipofectamine 2000 
according to the manufacturer’s protocol (Life Technologies). One day after transfection, 
cells were transferred into fresh DMEM medium containing 800 µg/ml Geneticin 




clones were separately expanded into two T-flasks each. Cells in one T-flask were 
harvested during the exponential growth phase and frozen in 10% DMSO for storage. 
Cells in the other T-flask were induced with 2 µg/ml tetracycline for 24 hrs, after 
reaching 80% confluency. Cells were then detached from the flask and washed with cold 
PBS. After adjusting the cell density to around one million cells per ml, protease 
inhibitors (Roche) were added and the cell suspension was frozen on dry ice in 1ml 
aliquots. NTSR1 expression levels were determined by [
3
H]NT binding and the clone 
with the highest expression level was selected for further experiments. 
2.3.5. Adaption of NTSR1-expressing T-REx-293 cells in to suspension culture 
Three different medium were tested for suspension culture of NTSR1-expressing 
T-REx-293 cells: Freestyle
TM
 293,  CD OptiCHO
TM
 (Gibco) and pro293 CD
TM 
Medium 
(Lonza). The adherent growth medium (DMEM supplemented with 10% certified FBS, 
5µg/ml blasticidin and 500µg/ml G418) was gradually replaced with suspension growth 
medium during subculture in T-flask. With the displacement of the media, increasing 
amount of viable detached cells can be collected and transferred into shake flask and 
maintained in suspension growth media supplemented with 1% certified FBS, 5 µg/ml 
blasticidin and 500 µg/ml G418 for suspension culture. The optimal media giving highest 
cell density and viability was chosen for further culture. 
2.3.6. Growth of T-REx-293 cell line suspension culture in a bioreactor 
The suspension-adapted T-REx-293 cells were grown in 5L of CD OptiCHO 




100 µg/ml streptomycin and 0.1% pluronic F-68 (Gibco), using a 10L glass bioreactor 
equipped with a pitch blade impeller connected to a Sartorius BDCU controller. The 
growth parameters were set to 37°C, pH 7, and 30% dissolved oxygen. The latter two 
parameters were maintained by interactive control delivery of air and CO2 through direct 
sparge (up to 10 ml/min). The speed of the impeller was 80 rpm. The cell density at 
inoculation was 3×10
5
 cells per milliliter. On day 5 after inoculation, expression of 
NTSR1 was induced by addition of 2 µg/ml tetracycline and 2.5 mM sodium butyrate 
(NaBu). Cells were harvested 36hrs after induction, re-suspended in hypotonic buffer (10 
mM Hepes pH 7.5, 10 mM MgCl2, 20 mM KCl), flash-frozen in liquid nitrogen and 
stored at –80C until use. 
2.3.7. Analytical solubilization of NTSR1 
Cell pellets from 10 ml of suspension cultures were suspended in Tris-glycerol-
NaCl buffer. Then the detergent DM and CHS was added to give a final buffer 
composition of 50 mM TrisHCl pH 7.4, 200 mM NaCl, 30% glycerol, 1% DM, and 0.1% 
CHS in a total volume of 2.5 ml. The samples were placed on a rotating mixer at 4C for 
1 hour. Cell debris and non-solubilized material were removed by ultracentrifugation 
(TL100 rotor, 60k rpm, 4°C, 30 min in Optima Max bench-top ultracentrifuge, 
Beckman), and the supernatants containing detergent-solubilized NTSR1 were used to 
determine the total number of expressed receptors by a detergent-based radio-ligand 
binding (see below). 




All buffer volumes relate to 1L of original cell culture. T-REx-293 cells were 
thawed and the volume was brought to approximately 200 ml with hypotonic buffer. The 
cells were then re-suspended using a Turrax T-25 (IKA) homogenizer at 8,200 rpm for 2 
min. After centrifugation (45Ti rotor, 40,000 rpm, 45 min, 4C, Optima L90K, 
Beckman), the membranes were resuspended (Turrax T-25) in approximately 120 ml of 
high-salt buffer (10 mM Hepes pH 7.5, 1 M NaCl, 10 mM MgCl2, 20 mM KCl) 
supplemented with DNaseI (final concentration 10 g/ml) and AEBSF (100 M), and 
centrifuged again. The high-salt washes were repeated 4 more times with the DNaseI 
addition omitted after the 2
nd
 wash. All subsequent steps were performed at 4C or on ice, 
and AEBSF (100 M final concentration) was repeatedly added throughout the 
procedure. The washed membranes were resuspended in a final volume of 40 ml of 
buffer (62.5 mM TrisHCl pH 7.4, 625 mM NaCl, 37.5% glycerol) containing 10 M 
neurotensin peptide. NTSR1 was extracted by drop-wise addition of 10 ml of a 5% DM / 
0.3% CHS solution. After 2.5 hours, the sample was clarified by centrifugation (45Ti 
rotor, 40,000 rpm, 1 hour, Optima L90K, Beckman), adjusted with imidazole to a final 
concentration of 20 mM, and then passed through a 0.2 m filter (Stericup). Next, the 
sample was loaded at a flow rate of 0.2 ml/min onto 2 ml Talon resin packed into an 
XK16 column (GE Healthcare) equilibrated with Talon-A buffer (50 mM TrisHCl pH 
7.4, 30% glycerol, 500 mM NaCl, 20 mM imidazole, 0.1% DM / 0.01% CHS) containing 
1 µM neurotensin peptide. After washing with 29 column volumes of buffer Talon-A, 
NTSR1 was eluted with Talon-B buffer (50 mM TrisHCl pH 7.4, 30% glycerol, 500 mM 




Peak fractions were collected (5 ml) and analyzed. The purification of NTSR1 from 
insect cells was performed in a similar manner. 
2.3.9. Protein analysis and radio-ligand binding assays 
The protein content was measured according to the Amido Black method of 
Schaffner and Weissmann [72] with bovine serum albumin as the standard. Western blot 
analysis was performed as described [73] using the INDIA HisProbe-HRP reagent 
(Pierce) and the substrates 3,3'-diaminobenzidine tetrahydrochloride and H2O2. 
[
3
H]NT ligand-binding assays with intact cells were carried out in 500 l of 
TEBB assay buffer (50 mM Tris-HCl pH 7.4, 1 mM EDTA, 0.1% bovine serum albumin, 
40 µg/ml bacitracin) containing 10 nM [
3
H]NT and about 100,000 cells. After incubation 
for 2-4 hours on ice, separation of bound from free ligand was achieved by rapid filtration 
through GF/B glass fiber filters (Whatman) pretreated with polyethylenimine. The 
amount of radioactivity was quantified by liquid scintillation counting (Beckman 
LS6500). Non-specific [
3
H]NT binding of 4160 dpm was subtracted from total binding to 
calculate the receptor density at the cell surface. The concentration of [
3
H]NT used in 
these assays was four-fold above the apparent dissociation constant for membrane-bound 
NTSR1 [67] to allow high receptor occupancy, but it kept nonspecific [
3
H]NT binding to 
a minimum. 
Ligand-binding assays with detergent-solubilized receptors were carried out in 
TEBB assay buffer containing 0.1% DDM, 0.2% CHAPS, 0.04% CHS. For one-point 
assays, receptors were incubated with 2 nM [
3




l. Separation of the receptor-ligand complex from free ligand (100 l) was achieved by 
centrifugation-assisted gel filtration using Bio-Spin 30 Tris columns (BioRad), 
equilibrated with RDB buffer (50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 0.1% DDM, 0.2% 
CHAPS, 0.04% CHS). Non-specific [
3
H]NT binding of 220 dpm was subtracted from 
total binding, and the amount of specifically bound [
3
H]NT was then corrected for 
fractional occupancy (apparent dissociation constants of 0.22 nM and 0.57 nM for 
receptors produced in HEK-293 cells and insect cells, respectively).  
For saturation binding experiments, the [
3
H]NT concentration was varied from 0.2 
nM to 10 nM. Non-specific [
3
H]NT binding was determined in the presence of 50 M 
unlabeled NT. Data were analyzed by nonlinear regression using GraphPad Prism 
software (version 4, GraphPad Software) and best fit to a one-site binding equation to 
determine the apparent dissociation constants for NTSR1 produced in insect and HEK-
293 cells. Note that the saturation binding experiments using the NTSR1 mutant did not 
reach equilibrium within the incubation time because of the very slow agonist off-rates 
determined in a previous study [67]. Individual experiments were conducted as single 
data points. 
  
2.4 - Results  
2.4.1. NTSR1 expression in suspension T-REx 293 cells  
For our study, we used the engineered rat neurotensin receptor NTSR1-GW5-i3 
(here referred to as NTSR1). This construct consists of the hemagglutinin signal peptide 




receptor NTSR1-GW5 (T43-K396 containing the mutations A86L, E166A, G215A, 
L310A, F358A, V360A)[67, 74] with the intracellular loop 3 residues G275-E296 
deleted. A deca-histidine tag was present at the C-terminus. The NTSR1 DNA was 
inserted into pACMV-tetO [51] using standard molecular biology techniques. The 
resulting expression vector pACMV-tetO-NTSR1 (Fig. 2.2) allows tetracycline inducible 
expression of NTSR1.  
The N-terminally truncated rat NTSR1 with 6 stabilizing mutations was stably 
expressed in the tetracycline-regulated T-REx-293 cell line. A high-expressing clone was 
selected and adapted step-wisely to suspension culture for scaling-up purposes. This 
clone grew to a density of 4 million cells /ml in shake flask with viability higher than 
95% and a doubling time of 48 hours. 
To maximize the production of NTSR1, a preliminary orthogonal array 
design[75] was carried out investigating three induction parameters: tetracycline 
concentration (1-4 µg/ml), sodium butyrate (NaBu) concentration (0.5-10 mM) and 
induction time (24-60 hrs). Initial variance analysis showed negligible impact from 
higher tetracycline doses, significant effect of NaBu, and considerable cell death with 
induction time longer than 48hr (data not shown). Therefore, further optimization efforts 
were focused on the NaBu dose with induction time of 24 or 36 hours. As shown in 
Fig.2.3, NTSR1 expression was undetectable in the absence of tetracycline, while in the 
presence of 2 µg/ml tetracycline, 2.5 million plasma membrane localized receptors were 
produced. The expression of functional NTSR1 improved with increasing NaBu 
concentrations (0.5-10 mM) and optimal production was achieved by the addition of 2 




million cells/ml, with harvest 36 hrs later. These optimized conditions resulted in 8.8 
million copies of NTSR1 localized at the plasma membrane per cell (Fig. 2.3), a 3.5-fold 
increase of cell surface expression compared to the induction with tetracycline alone. 
Pilot-scale production of NTSR1 was then carried out in a 5L bioreactor. 2µg/ml 
tetracycline and 2.5 mM NaBu were added to T-REx-293 cells when viable cell density 
reached 1.5 million cells/ml. Cells were harvested 36 hrs after induction and plasma 
membrane localized receptors were determined to be 5.6 million per cell with [
3
H]NT 
binding assays on intact cells. To determine the total amount of functional NTSR1 (i.e. 
receptors residing in the endoplasmic reticulum, the Golgi apparatus and plasma 
membrane), cells were solubilized with detergent and the number of receptors were 
determined by a detergent-based radio-ligand binding assay. This resulted in 18.2 million 
receptors per cell and a yield of 1.5 mg of functional NTSR1 per liter culture (Table 2.1).  
2.4.2. NTSR1 expression in insect cells 
Both Sf9 and T. ni cells were tested as insect hosts for NTSR1 expression and all 
subsequent pilot-scale expression experiments were performed using T. ni cells due to 
their higher viability after infection (we considered cell viability an essential factor as 
only healthy cells have an intact machinery for insertion and folding of membrane 
proteins).  T. ni cells were infected at an MOI of 5 followed by the reduction of 
temperature to 21C and cells were harvested at 48 hrs post-infection. NTSR1 was 
produced at a total number of 17.8 million receptors per cell or 1.7 mg receptor per liter 




2.4.3. Purification of NTSR1 from T-REx-293 cells and insect cells 
The presence of neurotensin enhance the stability of NTSR1-GW5-i3 [67], 
therefore, all purification steps were conducted in the presence of the agonist peptide. 
The purification of NTSR1 produced in T-Rex-293 and insect cells was done in one step 
by immobilized metal affinity chromatography (Talon resin) in the presence of the 
detergent DM/CHS. The yield of NTSR1 per liter of cell culture, as calculated from the 
cell density at harvest and [
3
H]NT binding assays on detergent-solubilized cells, was 
similar for both expression hosts (Table 2.1). The protein yield of the Talon column 
eluates was determined by the Amido Black method, as the presence of NT during the 
purification procedure prevented a radio-ligand binding analysis. Note that because of 
background contaminants (Fig.2.4), the Amido Black method overestimates the content 
of purified NTSR1.  
2.4.4. Characterization of NTSR1 produced in insect cells and T-Rex-293 cells 
To quantify the total amount of NTSR1 and the amount of plasma membrane 
localized NTSR1, [
3
H]NT binding assays on detergent-solubilized cell extracts and on 
intact cells were conducted. The total number of functional NTSR1 per cell, produced in 
T-Rex-293 cells and insect cells, was similar (Fig. 2.5A). T-Rex-293 cells produced 12.8 
million receptors per cell, while insect cells produced 15.8 million receptors per cell. 
However, the percentage of NTSR1 molecules that had trafficked to the cell surface was 
2.5-fold higher in the case of T-Rex-293 cells compared to insect cells (Fig. 2.5B). 




was performed and analyzed using INDIA HisProbe reagent, which detected all histidine 
tagged NTSR1. Equivalent amount of correctly folded NTSR1 (as determined by [
3
H]NT 
binding assays) from the two hosts were applied and the comparable band intensity 
indicated comparable total NTSR1 expression (including correctly folded and misfolded 
ones), thus suggesting similar propensity for receptor misfolding in T-Rex-293 and insect 
cells (Fig.2.4, lane 4 and 5).  
The ligand binding property of the receptors produced in the two hosts were 
comparable according to saturation binding assays using detergent-solubilized receptors. 
The dissociation constants for NTSR1 from both hosts were not statistically different 
(Fig. 2.6). 
 
2.5 - Discussion  
Unveiling the protein structure of GPCRs by crystallography will help to 
elucidate the mechanism of many diseases and enhance potential drug discovery and 
development. In order to accomplish this, milligram amounts of functional receptors are 
needed. Seeking an appropriate expression host is vital, as the host can affect the quantity 
and quality of the starting material [76]. Possible host choices include bacteria [77], yeast 
[78], baculovirus- insect cell system [79], and mammalian cells[80]. The baculovirus- 
insect cells system and inducible T-REx- 293 system were intensively investigated in 
recent years because of their lipid composition, translocation machinery and protein 




baculovirus- insect cell and mammalian T-REx- 293 system were compared throughout 
NTSR1 expression and purification process in a quantitative way. 
By using inducible expression strategy, 2.5 million functional copies of NTSR1 
per cell were detected on plasma membrane of T-REx cells; this level of expression is 
167 fold higher than the NTSR1 constitutively expressed in HEK-293T cells [38]. 
Optimization of induction parameters led to a further increase in expression level to 8.8 
million functional receptors per cell on plasma membrane. Among the three induction 
parameters tested (tetracycline concentration, NaBu concentration and time length of 
induction) the concentration of sodium butyrate (NaBu) had the most impact. This 
compound has been successfully applied together with tetracycline for synergistic 
induction of many GPCRs expression [81, 82]. NaBu is routinely used at low 
concentration (1-5mM[83]), possibly because of its cytotoxic effects on cell growth[84]. 
In the experiments reported here, NaBu was applied at a concentration of 10mM resulting 
in improved receptor expression. The enhancement of NTSR1 gene transcription by 
inhibition of histone deacetylase may be a possible explanation. It is also possible that 
NaBu led to growth arrest of host cells, allowing available energy be channeled to the 
NTSR1 expression pathway.  
Expression levels and binding properties of functional NTSR1 from the T-REx-
293 and baculovirus insect cells systems were comparable. For both systems, the yields 
were approximately 15 million total functional receptors per cell or 1 milligram per liter 
culture after purification. This indicates that a 10L culture will provide approximately 




point of view, a significant difference was observed in the surface-presentation of the 
receptors. In T-REx-293 cells, 2.5 times more NTSR1 were trafficked to the plasma 
membrane than insect cells as determined by ligand binding assays. The assumption was 
that higher surface-presentation is correlated with more properly folded receptors which 
were found to be the case for the serotonin transporter [76]. However, when equal 
amount of functional NTSR1 from both hosts were analyzed by western blot where 
INDIA HisProbe reagent would capture histidine tag of functional and non-functional 
NTSR1, the bands have similar intensity. This indicated comparable NTSR1 folding 
efficiency in both systems. Also, the fact that NTSR1 from insect cells could crystallize 
[67] suggested the difference between surface and internal receptors could be subtle. 
More studies will be needed in order to understand the implications of difference in 
receptor surface- presentation. 
Another difference between the transient expressions in the insect cells and the 
stable expression in the T-REx-293 cells is the timeframe required for process 
development and for establishing the expression conditions (Fig. 2.7). The estimated time 
for expression with baculovirus-insect cells is around 6 weeks while it can take up to 12 
weeks to obtain products from the stable T-REx-293 expression system. Based on this 
time frame the transient expression system is better at an early stage of the research when 
the GPCR of interest is subject to frequent sequence modifications for identifying 
constructs which are suitable for crystallization.  Whereas stable expression in suspension 
T-REx-293 cells may be preferable for production of GPCRs of a specified construct due 
to its superior processing capabilities. The well-established scale-up methods for 




sufficient amounts of receptors for other applications of biophysical techniques such as 
NMR spectroscopy. Cost-wise, the medium prices for T-REx-293 and insect cells are 
comparable. It is likely possible that improvement in high density suspension culture of 
T-REx-293 cells will further reduce cost per milligram of protein.  
In conclusion, we generated a suspension stable T-REx-293 cell line capable of 
expressing 1.5 milligram functional NTSR1 per liter. This cell line was found to be 
comparable to the transient baculovirus-insect cell expression system in regard to 
functional NTSR1 expression level and receptor binding properties. It provides a superior 
receptor surface display of the target proteins which may be advantageous for certain 
applications. 
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Figures and tables 
Fig.2.1. Illustration of the tetracycline inducible expression system. (A) In the absence of 
tetracycline, TetR binds to tetO2 downstream of the TATA element, thus blocking 
transcription of the gene of interest. (B) The interaction of tetracyline with TetR causes 












Fig.2.2. Construction of the NTSR1 expression vector. The NTSR1 DNA was inserted 
into pACMV-tetO using standard molecular biology techniques. The resulting expression 
vector allows tetracycline inducible expression of NTSR1 under control of CMV 
promoter. 
 














Fig.2.3. Optimization of NTSR1 expression under different induction conditions using a 
stable T-REx-293 cell line. The data were collected from a selected high-expressing 
clone. Cells were grown in suspension and were induced in the late exponential growth 
phase (at a viable cell density of 2 million cells /ml) with tetracycline. The addition of 
sodium butyrate enhanced expression levels. Intact cells were subjected to [
3
H]NT 






Fig.2.4. Purification of NTSR1. The progress of purification was monitored by SDS-
PAGE (NuPAGE 4–12% Bis-Tris gel, Invitrogen, 1x MES SDS buffer) and SimplyBlue 
staining. Lane 1: Novagen Perfect Protein Marker (15–150 kDa); lane 2: Talon eluate of 
NTSR1 produced in T-REx-293 cells (3.5g); lane 3: Talon eluate of NTSR1 produced 
in insect cells (6 g); Western blot analysis of total cell extract was performed using the 
HisProbe-HRP reagent recognizing the histidine tag. Lane 4: NTSR1 produced in T-REx-
293 cells (122,000 lyzed cells with 113 ng functional NTSR1); lane 5: NTSR1 produced 









Fig.2.5. Expression of NTSR1 in the transient insect cell system and inducible T-REx-
293 system. (A) Total functional NTSR1 numbers were determined by [
3
H]NT binding 
assays using detergent solubilized cells (B) Surface localized NTSR1 numbers were 
determined by [
3
H]NT binding assays using intact cells and combined with data from (A) 
to calculate percentage of surface localized NTSR1. (baculovirus insect cell system: 7 
independent expression experiments; T-REx-293 system: 3 independent measurements 
on one 5L expression experiment). The expression of NTSR1 in insect cells was 
conducted as described in Materials and Methods. Expression of NTSR1 in the T-REx-
293 system was induced by the addition of 2 µg/ml tetracycline and 10 mM sodium 









H]NT saturation binding of NTSR1 expressed in (A) T-REx-293 cells and (B) 
insect cells. NTSR1 was extracted from membranes with the detergent DM/CHS and 
subjected to radio-ligand binding analysis. Inset: Scatchard transformation. 
Representative experiments conducted as single data points are shown. (C) Table 
summarizing the values of the apparent dissociation constants values for [
3
H]NT binding. 
These values were not statistically different (P = 0.2, unpaired two-tailed t-test). Data 









0.22 ± 0.06 






Fig.2.7. Timeframe for establishment of transient baculovirus- insect cells system and 
















Table.2.1. Purification of NTSR1 from different host cells. Average data for insect cells 
were from four purification experiments using 1L (3 experiments) or 4L (1 experiment) 
of cell culture as starting material. Average data for T-REx-293 cells were from two 
purification experiments using 1L of culture as starting material. All purification 
procedures were performed in the presence of neurotensin. The theoretical yield was 
calculated from the cell density at harvest and [
3
H]NT binding assays on detergent-
solubilized cells. The protein yield of the Talon column eluate was determined by the 
Amido Black method, as the presence of NT during the purification procedure prevented 
a radio-ligand binding analysis. Because of minor contaminants in the Talon column 
eluate, the content of NTSR1 is overestimated. 
a
 average data from three 5L expressions, 
b
 data from one 5L bioreactor run. 
Host cell 
Functional receptor produced Functional receptor 
purified   (mg/L) (10
6
/cell) (mg/L) 


















NTSR1, neurotensin receptor type 1; GPCR, G protein-coupled receptor; HEK, human 
embryonic kidney; CHO, Chinese hamster ovary; ORF, open reading frame; pri-miRNA, 
primary miRNA; pre-miRNA, precursor miRNA; RISC, RNA-induced silencing 
complex; 3’-UTR, three prime untranslated region; CMV, cytomegalusvirus; DMEM, 
Dulbecco’s modified Eagle’s medium; PBS, phosphate-buffered saline; FBS, fetal bovine 
serum; GFP, green fluorescent protein; MAD, median absolute deviation; DMSO, 
Dimethyl sulfoxide; NT, neurotensin; DDM, n-dodecyl--D-maltopyranoside; CHS, 
cholesteryl hemisuccinate Tris salt; CHAPS, 3-[(3-cholamidopyropyl) 
dimethylammonio] -1- propanesulfonate; GPC3, glypican-3; BSA, bovine serum 
albumin; MOF, mean of fluorescence. 
 
3.1 - Summary 
 To explore the possibility of enhancing protein expression using miRNA, a stable 
T-REx-293 cell line was constructed to over-express the neurotensin receptor type 1 
(NTSR1) fused with green fluorescent protein (GFP) to its C-terminal. The cell line was 
then subjected to high-content image-based human miRNA mimic library screening. Five 
microRNA mimics: hsa-miR-22-5p, hsa-miR-18a-5p, hsa-miR-22-3p, hsa-miR-429 and 
hsa-miR-2110 were identified to improve functional expression of NTSR1 by as much as 




same human miRNA mimic library. All five identified microRNA mimics were also 
found to enhance the luciferase expression up to 239%. Interestingly, all five miRNAs 
improved glypican-3 hFc fusion protein secretion up to 120%, which indicated that these 
molecules could have a wide role in enhancing production of proteins with biomedical 
interest.  
 
3.2 - Introduction 
As discussed in chapter 2, the HEK293 cells were demonstrated advantageous for 
NTSR1 expression in many aspects. They have high functional expression level and 
surface display ratio of the receptor. They can reach high cell density (4-8 million 
cells/mL) in bioreactors and have continuous production capability. In addition, the high 
cost associated with FBS has been brought down by serum-free suspension culture, 
making the using of the expression system cost-effective. In all, the HEK293 expression 
system is a good choice for large-scale production of proteins for medical or structural 
studies, especially for expression of mammalian integral membrane proteins such as 
receptors, ion channels and transporters [7]. 
In this chapter, the goal is to use NTSR1 as a model integral membrane protein 
and to engineer the preferred HEK293 expression system to improve its production 
capability of heterologous membrane protein.  As discussed above and in chapter 1, 
rational engineering of the host cells may be trial and error due to the lack of thorough 
understanding in membrane protein biogenesis process. Thus, we chose a bottom-up 
approach, where host cells were treated by an entire library of engineering tools  




format, for identification of the best sequences that significantly enhanced NTSR1 
expression. These top sequences can be investigated in-depth in the future, to decipher 
the complex membrane protein expression process and provide reference for synthetic 
biology studies. 
The powerful engineering tools used in this chapter are miRNAs. They have been 
used for engineering cells with desirable properties[85], such as improved protein 
production capabilities[86] and enhanced anti-apoptotic properties under stress 
conditions[44, 87]. MiRNAs are a novel class of small, non-coding RNAs that can 
simultaneously silence multiple genes by binding to their 3’-untranslated regions(3’-
UTR)[88]. The miRNA development process starts in the nucleus. Following 
transcription, the several kb long primary miRNA (pri-miRNA) with a step-loop structure 
is cleaved by an endoculease III (Drosha) to generate a 70-nucleotide long precursor 
miRNA (pre-miRNA)[89]. After being transported to the cytoplasm, the stem-loop pre-
miRNAs is cleaved by another endoculease III (Dicer), to generate the final mature 
miRNA duplex with a length of 18-25 nucleotides. The guide strand of the miRNA 
duplex is then loaded into the RNA-induced silencing complex (RISC) and guides the 
complex to the complementary 3’-UTR of targeting mRNAs. The degree of 
complementarity determines the mechanism of the post-transcriptional inhibition 
function. With high complementarity, target mRNA is degraded via RNA interference 
process, whereas insufficient complementarity is predictive of a translational repression 
mechanism. 
MiRNAs  exhibit a broad spectrum of regulatory effects in eukaryotic cellular 




development and progression[85]. Their capacity to globally regulate entire gene 
networks[90] and to introduce no additional translational burden (compared to gene 
overexpression strategies)[91] makes them particularly advantageous for cell line 
development.  
In this chapter, we explore the ability to improve the receptor expression by 
applying the powerful miRNAs tool. The NTSR1-GFP-expressing HEK293 cells were 
subject to a high-throughput image-based screen with a human miRNA mimic library 
comprising 875 miRNA mimics. Excitingly, 5 top miRNA mimics identified from the 
screen not only improved NTSR1 functional expression level, but also significantly 
enhanced production of luciferase (intracellular protein) and an Fc fusion chimeric 
protein in HEK293 cell lines. 
  
3.3 - Materials and Methods: 
3.3.1 Construction of expression plasmid pJMA-NTSR1-GFP 
Truncated wild type NTSR1 (T43-K396) was subcloned into the tetracycline 
inducible plasmid pJMA111(a kind gift from Dr. Christopher G. Tate) replacing the 
serotonin transporter construct using KpnI and NotI restriction sites. Thus NTSR1 was 
placed downstream of the tetracycline-controlled CMV promoter and had an eGFP-deca-
histidine tag fused to its C-terminal (Fig. 3.1)[92]. 
3.3.2 Construction of stable NTSR1-GFP-expressing T-REx-293 cell line 
The T-REx-293 cell line was maintained as an adherent culture in DMEM 




transfected with the plasmid pJMA-NTSR1-GFP using Lipofectamine 2000 according to 
the manufacturer’s protocol (Life Technologies). One day after transfection, cells were 
transferred into fresh DMEM medium containing 200 µg/mL zeocin (Invitrogen) and the 
medium was replaced every three days. Two weeks later, ten cell clones were separately 
expanded into two T-flasks each. Cells in one T-flask were harvested during the 
exponential growth phase and frozen in 10% DMSO for storage. Cells in the other T-
flask were induced with 1 µg/mL tetracycline for 24 hrs, after reaching 80% confluency. 
Cells were then detached from the flask and washed with cold PBS. After adjusting the 
cell density to ~1×10
6
 cells per mL, protease inhibitors (Roche) were added and the cell 
suspension was frozen on dry ice in 1mL aliquots. NTSR1 expression levels were 
determined by [
3
H]NT binding and the clone with the highest expression level was 
selected for further experiments. The selected stable T-REx-293-NTSR1-GFP high 
expressor was then routinely maintained in DMEM containing 10% certified FBS, 5 
µg/mL blasticidin and 200 µg/mL zeocin. 
3.3.3 High-throughput miRNA screen 
T-REx-293-NTSR1-GFP cells were screened with a miRNA mimic library 
(Qiagen) based on Sanger miRBase 13.0 and consisting of 875 miRNAs mimics. For 
transfection, 0.8 pmol of each mimic was spotted to 384 well plate wells (Corning) and 
20 μL of serum-free DMEM containing 0.1 μL of Lipofectamine RNAiMax (Life 
Technologies) was then added to each well. This lipid-miRNA mixture was incubated at 
ambient temperature for 30 min prior to adding 2000 cells in 20 μL of DMEM containing 




hours  and induced with 1µg/mL tetracycline for 24 hours for NTSR1-GFP expression. 
Cells were then fixed with 2% paraformaldehyde (Electron Microscopy Sciences), 
stained with Hoechst 33342 (Life Technologies) for 45 minutes and gently washed with 
PBS. Plates were imaged with an ImageXpress Micro XL (Molecular Devices). Total cell 
number and per cell green fluorescence intensity were calculated using MetaXpress 
software (Molecular Devices) employing the Multi-Wavelength Cell Scoring application 
module. All screening plates had a full column (16 wells) of Silencer Select Negative 
Control #2 (Life Technologies) and the median value of each plate’s negative control 
column was used to normalize corresponding sample wells. A full column of positive 
control siRNA targeting GFP (GFP-22 siRNA, Qiagen) was also used as on-plate 
reference for transfection efficiency. The median absolute deviation (MAD) - based z-
score was calculated for each sample [93]. 
3.3.4 Validation transfection 
Validation transfections were performed in 12-well plates with miScript miRNA 
mimics (Qiagen, Cat.No. 219600-S0), SilencerSelect Negative Control #2 and with lethal 
control siRNA (Qiagen AllStars Cell Death Control) served as a control for transfection 
efficiency. Cells were transfected as described for screening except 0.15 million cells 
were transfected with 40nM miRNA using 6.25ul Lipofectamine RNAiMax in a total 
volume of 1mL of media. 72 hours after transfection, cells were induced with 1µg/mL 
tetracycline. 24 hours later, cells from each well were detached with non-enzymatic cell 
dissociation buffer (Gibco, Cat. No. 13150-016) and washed twice with cold PBS. Cell 




quantification system (Roche, Mannheim, Germany). Based on the counts, cell densities 
were adjusted to 0.5 million cells/ml with PBS and then subject to flow cytometry 




3.3.5 Flow cytometry analysis 
Cells harvested from validation transfection step were diluted to 0.2 million 
cells/ml with cold PBS for flow cytometry analysis. Green fluorescence was measured 
with Guava Easycyte 5HT and Incyte software (Millipore). The green fluorescence signal 
and cell gating were adjusted using uninduced T-REx-293-NTSR1-GFP cells, with more 
than 99.5% of the cells in low fluorescence range (<100). The setting was kept same for 
acquisition of all cell samples. 
3.3.6 Analytical solubilization of NTSR1 
 The detergents n-Dodecyl-β-D-maltoside (DDM), 3-[(3-cholamidopyropyl) 
dimethylammonio] -1- propane sulfonate (CHAPS) and cholesteryl hemisuccinate Tris 
salt (CHS) were obtained from Anatrace. Cell pellets from 2 mL of suspension culture 
were suspended in Tris-glycerol-NaCl buffer. Then the detergents DDM, CHAPS and 
CHS were added to give a final buffer composition of 50 mM TrisHCl pH 7.4, 200 mM 
NaCl, 30%(v/v) glycerol, 1% (w/v) DDM, and 0.6%(w//v) CHAPS and 0.12%(w/v)  
CHS in a total volume of 0.5 mL. The samples were placed on a rotating mixer at 4C for 
1 hour. Cell debris and non-solubilized material were removed by ultracentrifugation 




Beckman), and the supernatants containing detergent-solubilized NTSR1 were used to 
determine the total number of expressed receptors by a detergent-based radio-ligand 
binding assay. 
3.3.7 Ligand binding assay 





Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu) was purchased from Perkin Elmer. 
Ligand-binding assays with detergent-solubilized receptors were carried out in TEBB 
assay buffer (50mM Tris pH 7.4, 1mM EDTA, 40µg/mL bacitracin, 0.1% BSA) 
containing 0.1% (w/v) DDM, 0.2% (w/v) CHAPS and 0.04% (w/v) CHS. For one-point 
assays, receptors were incubated with 2 nM [
3
H]NT on ice for 1 hour in a volume of 150 
µL. The concentration of [
3
H]NT used was at least 5-fold above the apparent dissociation 
constants for detergent-solubilized NTSR1 to allow high receptor occupancy. Separation 
of the receptor-ligand complex from free ligand (100 µL) was achieved by 
centrifugation-assisted gel filtration using Bio-Spin 30 Tris columns (BioRad), 
equilibrated with RDB buffer (50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 0.1% (w/v) 
DDM, 0.2% (w/v) CHAPS, 0.04% (w/v) CHS). Non-specific [
3
H]NT binding of 220 dpm 
was subtracted from total binding to calculate the total amount of receptors in T-REx-
293-NTSR1-GFP cells. The number of functional NTSR1 was estimated by specific 
[
3
H]NT binding assuming one ligand-binding site per receptor molecule. The number of 
cells in the assay was derived by cell counting at cell harvest. This approach led to the 
calculation of the parameter “receptors/cell”. 




HEK-CMV-Luc2-Hygro cell line constitutively expressing luciferase is purchased 
from Promega. Transfections were performed in 12-well plates with miScript miRNA 
mimics (Qiagen, Cat.No. 219600-S0), SilencerSelect Negative Control #2 and lethal 
control siRNA (Qiagen AllStars Cell Death Control) served as a control for transfection 
efficiency. Cells were transfected in duplicates as described for screening except 0.1 
million cells were transfected with 40nM miRNA using 6.25ul Lipofectamine RNAiMax 
in a total volume of 1mL of media. 72 hours after transfection, 500μL of ONE-Glo™ 
Reagent (Promega) was added to one set of replicates for luciferase activity 
quantification and 500μL of CellTiter-Glo™ Reagent (Promega) was added to the second 
set of replicates for viable cell density measurement. All plates were incubated at room 
temperature for 20 minutes to stabilize luminescent signal and then measured with 
SpectraMax i3 plate reader (Molecular Devices). Per cell luciferase production can be 
calculated from overall luciferase activity and viable cell number. 
3.3.9 Application with GPC3-hFc-expressing cells 
HEK- GPC3-hFc cell line constitutively secreting glypican-3 hFc-fusion protein 
(GPC3-hFc) is a kind gift from Dr. Mitchell Ho’s group from National Institutes of 
Health. Cells were grown in DMEM supplemented with 10% FBS in a humidified 
incubator set at 37ºC and 5% CO2. Cells were transfected in 12-well plates as described 
for screening except 0.15 million cells were transfected with 40nM miRNA using 6.25ul 
Lipofectamine RNAiMax in a total volume of 1mL of media. 7 days after transfection, 
cell culture supernatant was collected and cleared using centrifuge for GPC3-hFc 




blue exclusion using a CEDEX cell quantification system (Roche, Mannheim, Germany). 
Per cell GPC3-hFc production can be calculated from overall GPC3-hFc yield and viable 
cell number.  
3.3.10 ELISA for GPC3-hFc concentration determination 
AffiniPure F(ab')2 Fragment Goat Anti-Human IgG (min X Bov, Ms, Rb Sr Prot, 
Cat. 109-006-170, Jackson Immunology) was used to coat a 96-well plate at 5μg/mL in 
PBS buffer, 50 μL per well, at 4 °C overnight. After the plate was blocked with 2% BSA 
in PBS buffer, pre-diluted cell culture supernatant was added, and the plate was incubated 
at room temperature for 1 h to allow binding to occur. After the plate was washed twice 
with PBS buffer containing 0.05% Tween 20, Peroxidase-conjugated AffiniPure Goat-
anti-uman IgG (Cat. 109-035-098, Jackson Immunology) was added at 1:4000 dilution, 
50ul/well. Following incubating at room temperature for 1 h, the plate was washed 4 
times and detected with Peroxidase Substrate System (KPL). 
 
3.4 - Results 
 
3.4.1 Construction of inducible T-REx-293-NTSR1-GFP cell line for image-based 
screen  
A stable cell line expressing wild type functional NTSR1-GFP fusion was 
constructed using the inducible T-REx system[68] by transfecting T-REx-293 cells with 




receptor expression level upon tetracycline induction was measured by [
3
H]NT binding 
assay (data not shown). A high-expressing clone producing 8.4 million receptors per cell 
was selected for further experiments. As seen in Fig.3.2, the receptors for this clone are 
located mostly on the plasma membrane as expected. 
3.4.2 High-throughput miRNA screen for enhanced NTSR1-GFP expression  
To identify miRNAs that improve NTSR1 expression in T-REx-293-NTSR1-GFP 
cells, the cells were screened with a library comprised of 875 human miRNA mimics. 
Cells were transiently transfected with mimics in 384-well format for 72 hours followed 
by tetracycline-induced expression of NTSR1-GFP fusion protein (Fig.3.3A). Twenty 
four hours after induction, the cells were fixed followed by nuclear staining. Each well 
was then imaged to obtain total cell number and per cell mean green fluorescent intensity 
(Fig.3.3B). Sample values were normalized based on the median value of each plate’s 
negative control column. A column of positive control siRNA capable of silencing gfp 
gene was also used as on-plate control for transfection efficiency. GFP-directed siRNA 
consistently provided a > 80% decrease in green fluorescence intensity. To assess 
reproducibility, the screen was performed in duplicate, resulting in a correlation 
coefficient of 0.92 (Fig.3.3C). Furthermore, the screen was completed again in replicate 
using cells from a different passage. The correlation between the two independent screen 
was 0.73. The median absolute deviation (MAD) - based z-score[93] was calculated for 
each sample, and the distribution of miRNA activity is plotted in Fig.3.3D. 40 miRNAs 
were shown to significantly increase NTSR1-GFP productivity (MAD-based z-score> 
2.0. Table 1) in both biological replicates and 26 of them (two thirds of total 40) were 





3.4.3 Validation of the selected miRNA candidates by flow cytometry analysis  
The expression level of NTRS1-GFP following transient transfection of the cells 
with the top 26 microRNA was measured by flow cytometry (Fig.3.4). The uninduced 
cells exhibited basal GFP expression with only 1% of cells exceeding the background 
fluorescence (10 
1
) (Fig.3.4A). Following transfection with negative control siRNA 
(siN.C.) and tetracycline induction, the expression of NTSR1-GFP caused a significant 
shift in the fluorescence intensity, resulting in a geometric mean of fluorescence (MOF) 
of 138. A further shift was observed when the cells were transfected with various miRNA 
mimics followed by tetracycline induction, including miR-129-5p, which led to a MOF of 
197. Compared with negative control siRNA, 14 of the 26 miRNAs resulted in an 
increased MOF. From this group, top 9 miRNAs were selected for further investigation 
(Fig.3.4B). Following the transfection with the 26 selected miRNAs, a large variance was 
seen in viable cell density (ranged from 54% to 135%, normalized to negative control) 
but not in viability (ranged from 84% to 97%) (Fig.3.4C).  
3.4.4 [
3
H]NT binding assay validation for improved functional expression of NTSR1  
The effect of the top 9 miRNAs on the functional expression of NTSR1 was also 
evaluated by measuring the functional activity of the receptor through the binding of 
labeled neurotensin ([
3
H]NT). Although all top 9 miRNAs were shown to improve 
NTSR1-GFP expression based on GFP fluorescence, only 5 of them (miR-22-5p, miR-
18a-5p, miR-22-3p, miR-429 and miR-2110) led to improved functional activity levels of 
NTSR1(Fig.3.5A). Of these, miR-2110-transfected cells expressed 13.8 million 




addition, miR-22-5p and miR-22-3p improved functional expression of NTSR1, by 30% 
and 21% respectively. As seen in Fig.3.5B a number of the top 9 miRNAs had negative 
effect on cell growth and viability.  
3.4.5 MiRNA screen for enhanced luciferase expression  
The human mimic miRNA library was also evaluated for its effects on the 
expression of luciferase in HEK293 cells constitutively expressing luciferase under 
control of a cytomegalovirus (CMV) promoter. Transfection was performed in duplicate 
in 384-well format. Seventy two hours post- transfection, one set of plates was assayed 
for luciferase and the other set was used for viable cell density (Fig.3.6A). Both 
luciferase activity and viable cell density were normalized to the median value of each 
plate’s negative control column and the luciferase expression per cell was calculated for 
each miRNA. Though luciferase and NTSR1 screen exhibited a limited correlation (R= 
0.31, Fig.3.6B), seven out of nine top hits identified from NTSR1 screen (Fig.3.6C) also 
significantly improved per cell luciferase productivity on a per cell basis (MAD-based z-
score>2.0).  
3.4.6 Validation of common hits 
The top 9 miRNAs identified from the NTRS1 screen were examined for their 
effects on luciferase activity in a 12-well plate format. Seven miRNAs improved 
luciferase activity from 50% to 239% (Fig.3.7A). MiR-892b and miR-22-3p showed the 
largest effect on luciferase expression with a 239% and 207% improvement respectively. 
Although these microRNAs inhibited cell growth (Fig.3.7B), the overall production of 
luciferase from cells transfected with miR-892b and miR-22-3p was still 188% and 127% 




miR-22-3p and miR-22-5p showed up as top common hits for NTSR1 and luciferase 
screen.  
3.4.7 Application of top common hits on secreted protein 
To investigate the impact of top common hits on secreted protein production, the 
five identified miRNAs(hsa-miR-22-5p, hsa-miR-18a-5p, hsa-miR-22-3p, hsa-miR-429 
and hsa-miR-2110) were independently transfected into HEK293 cell line stably 
expressing secreted hFc-fusion protein: glypican-3 hFc-fusion protein (GPC3-hFc) [94]. 
All five miRNAs enhanced per cell GPC3-hFc secretion (up to 120% improvement, Fig. 
7A), while three miRNAs (hsa-miR-22-5p, hsa-miR-18a-5p and hsa-miR-22-3p) 
effectively enhanced overall GPC3-hFc (up to 62%, Fig. 3.8C).   
 
3.5 - Discussion: 
Integral membrane proteins such as mammalian receptors, ion channels and 
transporters are vital for medical research. However, obtaining large amounts of 
functional membrane proteins for medical research, especially structural studies, has been 
difficult and therefore been a barrier for productive research towards better understanding 
of their mechanisms and potential medical use [7, 8, 11]. So far, a tetracycline-inducible 
mammalian expression system [68] has been shown to be an effective method for 
functional expression of membrane proteins [50, 51, 76]. This inducible system together 
with optimized production conditions led to a yield of 1 milligram per liter of purified 
NTSR1 in chapter 2. Compared with well-developed prokaryotic hosts such as E.coli, the 
production of membrane proteins from higher eukaryotic hosts is still in the stage of “trial 




insertion, folding and trafficking are not completely understood. 
To improve the production of these proteins, a bottom-up screening approach using 
human miRNA mimics library was implemented to identify candidates that lead to 
improved expression of the GPCR from the T-Rex-293 cells. This approach has 
previously proven effective for apoptosis screening[87] and recombinant secreted protein 
screening[96, 97] in CHO cells. In this study, we developed an image-based high-
throughput screening method to detect per cell green fluorescence signal, which is 
applied as a proxy for the number of molecules of NTSR1 protein expressed per cell. In 
addition to its high reproducibility (0.92 correlation between technical replicates), this 
method is cost-effective for protein labeled with fluorescent, as no secondary reagent is 
needed for protein quantification. . It is also high throughput and high-capacity, as cells 
are fixed and the screening is not time-sensitive compared to live-cell processes such as 
flow cytometry. This screen methodology can be applied to other membrane or 
intracellular protein candidates when the targeted protein is fused with GFP.  Although 
GFP fusion has been widely used for membrane protein overexpression screen and 
purification in a variety of hosts [98-100], it is possible that the N-terminal GFP fusion 
may mask signal sequence essential for protein insertion. This may compromise folding 
or correct localization of the desired membrane protein [101, 102]. C-terminal GFP 
fusion, on the other hand, is preferable as it is generally better in maintaining the 
localization and function of the native protein [101] with exceptions when C-terminal 
contains an essential functional segment [103, 104].  
Among the 875 human miRNA mimics tested, 40 mimics consistently led to 




MAD-based-z-score higher than 2.0. Among the top 40 candidates, miR-892b, miR193b-
3p and miR-193a-3p share the same seed sequence (ACUGGC), indicating that they may 
comprise an overlap in target genes. Similarly, miR-129-3p and miR-129-1-3p also share 
a same seed sequence (AGCCCU). 
The activity of two thirds of the 40 mimics was confirmed further by flow 
cytometry and the 9 mimic candidates contributing to the highest per cell green 
fluorescence signal were further tested in the [
3
H]NT binding assay. Five out of the nine 
mimics showed up to 48% improvement in functional expression of NTSR1. From these 
five, miR-2110 is a novel miRNA that has been identified but not studied[105]. The other 
four miRNAs (miR-429, miR-18a-5p, miR-22-5p and miR-22-3p) have been associated 
with cancer research in which they have exhibited contradicting effects on cell 
proliferation, cell growth, and protein production depending on the cell type and stage of 
cell development[86, 106-111]. For example, miR-429, a member of the miR-200 family, 
was  shown to suppress tumor growth in human osteosarcoma[107], while  in non-small 
cell lung cancer (NSCLC), the same miRNA  is suggested as a potential target for 
NSCLC due to its promotion of cell proliferation[106]. miR-18a-5p is part of the miR-17-
92 precursor sequence cluster, which is also named Oncomir-1. This miR-17-92 cluster 
was studied in depth regarding its effect on recombinant EpoFc protein production in 
CHO cells. Although  over-expression of the entire cluster  decreased productivity while 
having no effect on cell growth, the over-expression of miR-17 and miR-92 were shown 
to increase production[86].  
Of the nine miRNAs that enhanced the expression of the NTSRI-GFP fusion 




with enhanced binding activity of the agonist in the [
3
H]NT assay. This may be an 
indication that NTSR1 could be misfolded in these cells following the enhanced 
expression. Another observation is that eight of the nine top hits (except miR-129-5p) 
caused a decrease in the viable cell number. One possible reason for this behavior is that 
overexpression of NTSR1-GFP could be toxic to the cells. Another possibility is that the 
introduction of a specific miRNA to the cells is associated with a growth arrest, leading to 
improved protein production[85, 112]. Since multiple pathways and genes can be targeted 
by one miRNA, it will be worthwhile to examine which specific genes are down-
regulated in these cells and to investigate the mechanism that improved NTSR1 
functional expression. 
In parallel to the analysis of the miRNA effect on the NTSR1 expression, an 
HEK293 cell line constitutively expressing luciferase under the control of CMV promoter 
was subjected to screening of the same miRNA mimics library. This screen showed low 
degrees of correlation (R= 0.31) with the NTSR1-GFP screen. The low correlation may 
be the result of the difference between biogenesis process of integral membrane proteins 
and intracellular soluble proteins; the difference between constitutive expression 
elements and the inducible expression system; and clonal differences between the two 
HEK293 cell line used. Despite the overall low correlation between the screens, seven 
out of nine top miRNAs (except miR-129-5p and miR-639) identified from NTSR1-GFP 
screen, improved luciferase activity from 50% to 239%. All the final five miRNAs (miR-
429, miR-18a-5p, miR-22-5p and miR-22-3p and miR-2110) capable of improving 
NTSR1 functional expression were also relevant for improving luciferase expression.  




application for other types of proteins. Therefore, they were tested with HEK293 cell line 
constitutively secreting an Fc fusion proteins with medical importance [94]. Interestingly, 
all of the five miRNAs were effective in enhancing per cell Fc fusion protein secretion. 
However, the overall Fc fusion protein yield varied from 10% decrease to 62% increase, 
partially depending on the viable cell number after miRNA transfection.  
 
Contributions from collaborators: 
Dr. Scott Martin contributed to conceiving and designing of RNAi screen experiments, 
data analysis and revising the manuscript. Yu-Chi Chen carried out luciferase miRNA 
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Fig.3.2. Confocal microscopy of tetracycline-induced T-REx-293-NTSR1-GFP cells with 






Fig.3.3. MiRNA screen with stable T-REx-293-NTSR1-GFP cell line. (A) Workflow of 
the screen. (B) Nuclei staining and GFP expression was captured by ImageXpress (C) 
Correlation plot of replicates from the miRNA library screen. (D) Distribution of miRNA 







Fig.3.4. Flow cytometry analysis on T-REx-293-NTSR1-GFP cells transfected with 26 
miRNAs selected from those MAD-based z-score>2.0. (A) Fluorescence histogram of 
un-induced cells (grey), induced cells transfected with negative control siRNA siN.C. 
(dash line) and induced cells transfected with miR-129-5p (solid line). (B) MOF from 
each sample was normalized to the negative control (siN.C). Top 9 miRNAs are 
indicated. (C) Normalized viable cell density and viability of cells transfected with 26 
miRNA hits. Three biological samples were collected for each transfection experiment. 





Fig.3.5. Validation of improved functional expression of NTSR1 with [
3
H]NT binding 
assay. (A) Functional NTSR1 numbers were determined by [
3
H]NT binding assays using 
detergent solubilized cells. (B) Cells were counted at harvest and normalized to the 
control (siN.C.). Two independent experiments were carried out with different passages 
of T-REx-293-NTSR1-GFP cells, and each independent experiment was tested in 






Fig.3.6. MiRNA screen with stable HEK-CMV-Luc2-Hygro cell line. (A) Workflow of 
the screen. (B) Correlation plot of screen result from luciferase screen and NTRS1-GFP 






Fig.3.7. Validation of improved luciferase activity. HEK-CMV-Luc2-Hygro cells were 
transfected in 12-well plates with the top 9 miRNAs in duplicate. 72 hours post 
transfection, one replicate was used for luciferase measurement and the other one was 
subject to cell counting. (A) Per cell luciferase activity was determined by ONE-Glo 
luciferase assay and viable cell density. (B) Viable cell density and (C) Overall luciferase 
production were normalized to the negative control (siN.C.). For each biological sample, 
the measurement was done in duplicates. The experiment was performed twice with 






Fig.3.8. Improved glypican-3(GPC3) hFc-fusion protein secretion by the five top 
miRNAs. (A) Per cell GPC3-hFc secretion was determined by ELISA and viable cell 
density. (B) Viable cell density and (C) Overall GPC3-hFc production were normalized to 
the negative control (siN.C.).The experiment was performed twice with different 
passages of cells. For each biological sample, the measurement was done in triplicates. 







Table.3.1. Top hits from human miRNA mimics screen based on per cell green 
fluorescence intensity (MAD-based z-score>2.0) 
Human miR 
ID (hsa-) 
Variant Mature miRNA  sequence 
MAD-based 
z-score 
Signal relative to 
negative control (%) 
miR-221 5p ACCUGGCAUACAAUGUAGAUUU 5.3 248 
miR-429 - UAAUACUGUCUGGUAAAACCGU 4.2 212 
miR-22 5p AGUUCUUCAGUGGCAAGCUUUA 4.0 215 
miR-892b - CACUGGCUCCUUUCUGGGUAGA 3.7 201 
miR-1974 - UGGUUGUAGUCCGUGCGAGAAUA 3.6 201 
miR-210 3p CUGUGCGUGUGACAGCGGCUGA 3.2 183 
let-7f-2 3p CUAUACAGUCUACUGUCUUUCC 3.0 178 
miR-130b 5p ACUCUUUCCCUGUUGCACUAC 2.9 178 
miR-188 5p CAUCCCUUGCAUGGUGGAGGG 2.9 177 
miR-301a 3p CAGUGCAAUAGUAUUGUCAAAGC 2.9 176 
miR-129 5p CUUUUUGCGGUCUGGGCUUGC 2.7 172 
miR-147a - GUGUGUGGAAAUGCUUCUGC 2.6 168 
let-7c 5p UGAGGUAGUAGGUUGUAUGGUU 2.6 168 
miR-1909 5p UGAGUGCCGGUGCCUGCCCUG 2.6 169 
miR-138-1 3p GCUACUUCACAACACCAGGGCC 2.5 167 
miR-193b 3p AACUGGCCCUCAAAGUCCCGCU 2.5 166 
miR-650 - AGGAGGCAGCGCUCUCAGGAC 2.5 163 




miR-10b 3p ACAGAUUCGAUUCUAGGGGAAU 2.4 162 
miR-2110 - UUGGGGAAACGGCCGCUGAGUG 2.3 160 
miR-22 3p AAGCUGCCAGUUGAAGAACUGU 2.3 158 
miR-193a 3p AACUGGCCUACAAAGUCCCAGU 2.3 156 
miR-340 3p UCCGUCUCAGUUACUUUAUAGC 2.3 159 
miR-649 - AAACCUGUGUUGUUCAAGAGUC 2.0 150 
miR-18a 5p UAAGGUGCAUCUAGUGCAGAUAG 2.0 149 
miR-192 3p CUGCCAAUUCCAUAGGUCACAG 2.0 148 
All mature miRNAs variants are shown: 5'-end pre-miRNA derived (marked 5p) and 3'-









Chapter 4: High-throughput genome-wide siRNA screen identifies important genes 
for improved heterologous protein expression  
 
Abbreviations: 
RNAi, RNA interference; siRNA, small interfering RNAs; RISC, RNA-induced silencing 
complex; FBS, fetal bovine serum; KEGG, Kyoto Encyclopedia of Genes and Genomes; 
MAD, median absolute deviation; RSA, redundant siRNA activity; NTSR1, neurotensin 
receptor type I; SERT, serotonin transporter; GFP, green fluorescent protein; RNP, 
ribonucleoprotein; snRNA, small nuclear RNA; hnRNP, heterogeneous nuclear 
ribonucleoprotein. 
 
4.1 - Summary 
Large-scale RNA interference has been developed and utilized as a revolutionary 
tool in deducing gene functions in many diseases. However, the genome-wide loss-of-
function data is very limited for heterologous protein production process. In this chapter, 
HEK293 cells constitutively expressing luciferase reporter were subject to a genome-
wide siRNA screen.  Among the 21,585 genes that were individually knocked down, 56 
genes were selected for validation screen and top 10 genes leading to the greatest 
improvement of luciferase production were identified. Interestingly, from KEGG 
pathway analysis, genes significantly improving luciferase expression were found to be 
highly enriched in splicesome pathway. In addition, the effects of top 10 genes on 
secreted and membrane proteins were investigated and the co-transfection of different top 




4.2 - Introduction 
RNA interference (RNAi), firstly discovered as a natural biological process of 
eukaryotic cells to protect the genome against foreign nucleic acids [113, 114], has been 
developed and utilized as a revolutionary tool in deducing gene functions and in 
combating genetic defects, viral diseases, autoimmune disorders, and cancers [115]. 
Following the discovery of double strand RNAs in Caenorhabditis elegans[116], 
chemically synthesized small interfering RNAs (siRNA) were shown to efficiently 
silence endogenous genes in mammalian cells [117, 118], providing the foundation for 
developing RNAi applications. SiRNAs are 21-25 nucleotide double strand RNA 
fragments with symmetric 2-nucleotides 3’-end overhangs [119]. The guide strand of 
siRNA can be incorporated into RNA-induced silencing complex (RISC), which brings 
about sequence-specific degradation of the homologous single stranded mRNAs[120].  
In recent years, large-scale genetic screens were made possible by the availability 
of genome-wide siRNA library as well as the development of sophisticated new 
instrumentation and bioinformatics approaches for data analysis [121, 122]. They have 
been used to interrogate the biological functions of specific genes and pathways in 
various diseases[123] and important biological process including signal transduction, cell 
aging or death, cell or organelle organization, protein localization and responses of host 
cells to pathogens[124-128]. However, the genome-wide loss-of-function data is very 
limited for heterologous protein production [124, 129], an important process being 
intensively investigated by pharmaceutical and biotechnology industry using genetic or 




In this work, we performed a genome-wide siRNA screen to identify genes 
involved in recombinant protein production using Photinus pyralis (firefly) luciferase as 
a reporter protein.  Luciferase is a 62kDa large multidomain enzyme that has been widely 
used as a reporter in cell biology[130]. As one of the first described large, multidomain 
proteins, luciferase has been intensively used to study co-translational folding of 
polypeptide and the role of chaperones in protein folding [131, 132]. Here, with high-
throughput format, 21,585 genes were individually knocked down with three different 
siRNAs in HEK-CMV-Luc2-Hygro cells constitutively expressing firefly luciferase.  The 
results from end-point viable cell number and luciferase activity measurement were 
cooperated into genome-wide loss-of-function data. Statistical data analysis was executed 
followed by validation screen, where top 10 genes leading to greatest improvement of 
luciferase production were confirmed. In this chapter, a brief overview of these top 10 
genes was provided and their effects on secreted and membrane proteins were also 
investigated. 
  
4.3 – Materials and Methods: 
4.3.1. High-throughput genome-wide screen for luciferase expression 
HEK-CMV-Luc2-Hygro cells constitutively expressing P. pyralis luciferase 
(Progema) were maintained in DMEM containing 10% fetal bovine serum (FBS) in a 
humidified incubator set at 37ºC and 5% CO2. The library for primary screen is the 
Silencer® Select Human genome siRNA library (Ambion), which targets 21,585 human 




transfection was done in duplicates: 0.8 pmol of each siRNA was spotted to 384 well 
plate wells (Corning) and 20 μL of serum-free DMEM containing 0.15 μL of 
Lipofectamine RNAiMax (Life Technologies) was then added to each well. This lipid-
siRNA mixture was incubated at ambient temperature for 30 min prior to adding 4000 
cells in 20 μL of DMEM containing 20% FBS (Gibco). After incubating transfected cells 
at 37ºC in 5% CO2 for 72 hours, 20 μL of ONE-Glo™ Reagent(Promega) was added to 
one set of replicates for luciferase activity quantification and 20 μL of CellTiter-Glo™ 
Reagent(Promega) was added to the second set of replicates for viable cell density 
measurement. All plates were incubated at room temperature for 20 minutes to stabilize 
luminescent signal and the signal was then measured with PerkinElmer Envision 2104 
Multilabel plate reader. All plates had a full column (16 wells) of Silencer Select 
Negative Control #2 (Life Technologies) for data normalization and a full column of 
AllStars Hs Cell Death Control siRNA was also used as on-plate reference for 
transfection efficiency.  
4.3.2. Statistical analysis of primary screen data and Kyoto Encyclopedia of Genes 
and Genomes (KEGG) pathway analysis  
For each plate, the median value of negative control column was set as 100% and 
was used to normalize corresponding sample wells. The luciferase activity and viable cell 
density was exported as % of negative control and the median absolute deviation (MAD) 
- based z-score was calculated for each sample [93]. The redundant siRNA activity 
(RSA) analysis  was performed as described[133] to rank candidate genes that enhance 




iterative hypergeometric test and p-values indicating the statistical significance of all 
wells targeting a single gene distributed toward the top ranking slots were generated for 
each gene. All genes with p <0.005 were imported for KEGG pathway analysis. For the 
pathway enrichment map, red color indicates lower p-value (p<0.001) thus higher rank of 
the genes; while pink color denotes lower rank (0.001<p<0.005). 
4.3.3. Validation screen  
For each of the top 54 genes selected from the primary screen, 3 independent 
Silencer® siRNAs (Ambion) with different sequences from the primary screen were 
seeded into 384-well plates. The transfection and assay process is the same as the primary 
genome-wide screen. 
4.3.4 Validation with GPC3-hFc-expressing cells 
HEK- GPC3-hFc cell line constitutively secreting glypican-3 hFc-fusion protein 
(GPC3-hFc)[94] is a kind gift from Dr. Mitchell Ho’s group from National Institutes of 
Health. Cells were grown in DMEM supplemented with 10% FBS in a humidified 
incubator set at 37ºC and 5% CO2. 
Validation transfections were performed in 12-well plates with Silencer or 
SilencerSelect siRNAs and SilencerSelect Negative Control #2 (Ambion). AllStars Cell 
Death Control (Qiagen) was used as lethal control for transfection efficiency. Cells were 
transfected in 12-well plates as described except 0.15 million cells were transfected with 




5 days after transfection, cell culture supernatant was collected and cleared using 
centrifuge for GPC3-hFc concentration determination with ELISA and cells were 
detached and counted by trypan blue exclusion using a CEDEX cell quantification system 
(Roche, Mannheim, Germany).  
4.3.5. ELISA for GPC3-hFc concentration determination 
AffiniPure F(ab')2 Fragment Goat Anti-Human IgG (min X Bov, Ms, Rb Sr Prot, 
Cat. 109-006-170, Jackson Immunology) was used to coat a 96-well plate at 5μg/mL in 
PBS buffer, 50 μL per well, at 4 °C overnight. After the plate was blocked with 2% BSA 
in PBS buffer, pre-diluted cell culture supernatant was added, and the plate was incubated 
at room temperature for 1 h to allow binding to occur. After the plate was washed twice 
with PBS buffer containing 0.05% Tween 20, Peroxidase-conjugated AffiniPure Goat-
anti-uman IgG (Cat. 109-035-098, Jackson Immunology) was added at 1:4000 dilution, 
50ul/well. Following incubating at room temperature for 1 hr, the plate was washed 4 
times and detected with Peroxidase Substrate System (KPL). 
4.3.6. Validation with cells producing membrane proteins in fusion with GFP 
HEK293 cell lines producing neurotensin receptor (NTSR1)-GFP fusion protein 
and serotonin transporter (SERT)-GFP fusion protein were independently tested with top 
10 siRNAs. The stable SERT-GFP-expressing cell line is a kind gift from Dr. Chris Tate 
[92](Andréll & Tate unpublished), and NTSR1-GFP-expressing T-REx-293 cell line was 




containing 10% certified FBS and 5 µg/mL blasticidin and 200 µg/mL zeocin 
(Invitrogen).  
Cells were transfected as described except 0.15 million cells were transfected with 
40nM siRNA using 6.25ul Lipofectamine RNAiMax in a total volume of 1mL of media. 
72 hours after transfection, cells were induced with 1µg/mL tetracycline. 24 hours later, 
cells from each well were detached with non-enzymatic cell dissociation buffer (Gibco, 
Cat. No. 13150-016) and washed twice with cold PBS. Cell densities and viability were 
determined by trypan blue exclusion using a CEDEX cell quantification system (Roche, 
Mannheim, Germany). Based on the counts, cell densities were adjusted to 0.5 million 
cells/ml with PBS and then subject to flow cytometry analysis.  
4.3.7. Flow cytometry analysis 
Cells harvested from validation transfection step were diluted to 0.2 million 
cells/ml with cold PBS for flow cytometry analysis. Green fluorescence was measured 
with Guava Easycyte 5HT and Incyte software (Millipore). The green fluorescence signal 
and cell gating were adjusted using uninduced T-REx-293-NTSR1-GFP cells, with more 
than 99.5% of the cells in low fluorescence range (<100). The setting was kept same for 
acquisition of all cell samples. 
4.3.8. Co-transfection with two of top 10 siRNAs 
HEK-CMV-Luc2-Hygro cells (Progema) were transfected in quadruplicate in 96-
well plates as described except 2.4×10
4
 cells were transfected using 0. 9μl Lipofectamine 




each with final concentration of 40nM. Luciferase activity was measured by ONE-Glo™ 
assay and viable cell density was measured by CellTiter-Glo™ assay. Wells containing 
80nM of Silencer Select Negative Control #2 siRNA were used to normalize all sample 
wells. 
 
4.4 - Results 
4.4.1. Primary genome-wide screen identifies a number of genes that enhance CMV 
driven luciferase expression in HEK293 cells.  
We conducted a human genome siRNA screen to identify genes and pathways 
associated with CMV driven luciferase activity. Screening employed a siRNA library 
targeting 21,585 human genes with 3 separately arrayed siRNAs per gene in HEK-CMV-
Luc2-Hygro cells. For the screen, the transfection was done in duplicates: one set of 
plates was used for overall luciferase yield measurement and the other set was used for 
viable cell number determination, from which the per cell luciferase expression can be 
calculated (Fig. 4.1A). Based on overall luciferase yield, the distribution of siRNA 
activity is illustrated in the histogram (Fig.4.1B). 1,778 siRNAs were able to significantly 
enhance luciferase expression (MAD-based z-score>3, or 40% to 178% increase than 
negative control), and they were categorized as ‘strong enhancers’. From the 1,778 
siRNAs, we identified 56 genes, which were targeted by at least two independent siRNAs 
from this ‘strong enhancer group’ and they were subject to validation screen.  
The overall luciferase yield could be resulted from either improved viable cell 




improved per cell luciferase expression by more than 20% (Fig. 1C quadrant I&II), while 
only 254(0.4%) siRNAs achieved more than 20% enhancement in viable cell number 
(Fig. 4.1C quadrant I&IV). Surprisingly, only 2 siRNAs were capable of improving both 
per cell luciferase expression and viable cell density by more than 20%. 
4.4.2. Validation screen for top 10 gene confirmation 
To further investigate many of the top candidates, additional three siRNAs were 
tested for the 56 ‘strong enhancer’ genes selected from 4.4.1 (Fig. 1B). The primary 
screen and validation screen data for the 56 genes were combined and top 10 genes 
(Table 4.1) were identified based on the criteria that least 3 out of 6 siRNAs tested had 
led to MAD-based z-scores higher than 3.0. Viable cell number was also taken into 
consideration to remove candidates with significant toxicity. The overall luciferase yield, 
per cell luciferase yield and viable cell numbers associated with the 6 siRNAs targeting 
one of the top 10 genes were summarized in Supplemental Table 4.S1. The median value 
of the overall luciferase yield for each gene was calculated from the 6 siRNAs (Table 
4.1). In summary, the median value of overall luciferase yield was improved by 24% to 
72% than negative control cells and the median of MAD-based z-scores range from 2.13 
to 4.55.  
Interestingly, 4 out of top 10 genes (ints1, ints2, hnrnpc and prpf19) are involved 
in mRNA splicing process. They all encode important proteins for splicesome formation, 
e.g. integrator complex, heterogeneous nuclear ribonucleoprotein and pre-mRNA 
processing factor 19. The rest of top genes encode proteins covered a wide span of 




regulation of cellular polyamine concentration, protein translation and folding (Table 
4.1).  
4.4.3. KEGG pathway analysis identifies splicesome as a statistically significantly 
enriched pathway for top genes 
To identify the pathways where the top candidate genes are enriched in, the 
redundant siRNA activity (RSA) analysis [133] was performed  to rank genes enhancing 
luciferase activity. Then 362 genes with p <0.005 from RSA analysis (Supplemental 
Table.4.S2) were imported for KEGG pathway analysis. Among the 362 genes, 28 were 
involved in splicesome pathway (p=6.4
-23
, Fig. 4.2).  The genes with higher rank 
(p<0.001, red) encode for important splicesome components, e.g. small nuclear 
ribonucleoprotein (Sm), splicing factor 3A (SF3a), heterogeneous nuclear 
ribonucleoproteins (hnRNPs), pre-mRNA-processing factor 19 (Prp19), etc.(Fig. 4.2). 
4.4.4. Test of top 10 genes with secreted and membrane proteins 
In order to investigate if the knock-down of identified genes will contribute to 
similar improvement in HEK293 cell lines expressing other proteins, three cell lines were 
tested.  HEK- GPC3-hFc cell line can constitutively secrete glypican-3 hFc-fusion protein 
(GPC3-hFc) [94] and was tested in this study as a representative of antibody secreting 
cell lines. T-REx-293-NTSR1-GFP cell line has been constructed previously for 
production of functional neurotensin receptor type I (NTSR1) in chapter 3.  T-REx-293-
SERT-GFP [92]( Andréll & Tate unpublished) is an inducible cell line for high level 




protein. Both NTRS1 and SERT were fused with GFP to their C-terminal, allowing 
proximal protein quantification with flow cytometry. As shown in Fig4.3, the top 10 
siRNAs demonstrated various effects on secreted and membrane proteins.  Notably, the 
knocking down of ints1, hnrhpc, oaz1 and ppp2r1a consistently improved the expression 
of all proteins tested. However, the knocking down of ints1 and hnrnpc led to 
significantly reduced viable cell number, indicating these genes may be essential for cell 
survival or cell growth. Silencing of oaz1and ppp2r1a gene showed minimal negative 
effects on viable cell number. 
4.4.5. Co-transfection with top 10 siRNAs 
To investigate the combinatorial effect of top siRNAs, HEK-CMV-Luc2-Hygro 
cells were transfected with two of top 10 siRNAs, each siRNA with final concentration of 
40nM. Per cell luciferase production upon co-transfection was calculated from overall 
luciferase activity and viable cell density and was summarized in Fig. 4.4. Cells 
transfected with 80nM of negative control siRNA were used for normalization and their 
per cell luciferase expression level was set as 100.  Depending on the genes of choice, the 
combinatorial effect can be positive or negative. For example, 80nM of siRNA against 
hnrnpc and ppp1r2a independently led to luciferase level of 299 and 251. When 40nM of 
both siRNAs were co-transfected while keeping the overall siRNA concentration at 
80nM, the luciferase level went up to 435. The negative effects can be observed with the 
co-transfection of siRNAs for casp8ap2 and eef1b2. They each independently led to 
luciferase level of 121 and 170 but the combination brought luciferase expression down 




We chose the best combination from binary co-transfection (hnrnpc and ppp1r2a) 
and added a third siRNA to explore further improvement. Maintaining the overall siRNA 
concentration at 80nM, 27nM of each siRNAs were co-transfected and the best 
combination is ints1 with hnrnpc and ppp1r2a.  Altogether, they led to luciferase level of 
463 and the addition of a fourth siRNA didn’t improve the expression level further (data 
not shown).  
 
4.5 - Discussion: 
Genome-wide RNAi screening has emerged to be a revolutionary and powerful 
tool for interrogating gene functions and for target discovery in various diseases [124-
128]. However, it has been scarcely used to identify targets for enhancement of 
recombinant protein production process. The screening in CHO cells was limited to 
miRNA library [87, 96, 97], as a proper synthetic hamster siRNA library is still lacking. 
To our knowledge, there have been two publications investigating protein secretion using 
human whole-genome siRNA libraries [124, 129]. However, both were focusing on 
disruption of secretory pathway with siRNA-mediated gene depletion as their goal was to 
identify genes required for protein secretion process. To the contrary, we identified genes 
that need to be down-regulated for improved recombinant protein production. Besides, 
our screening is not limited to secretion process. Indeed, the identified gene targets 
covered a variety of functions, including DNA replication, mRNA splicing, translation, 




In contrast to miRNA screening from chapter 3, which requires intensive follow-
up work on gene targets identification through microarray or next-gen sequencing 
studies, siRNA screening gives direct correlation between the arrayed siRNAs and gene 
targets. This allows faster gene indentification and construction of stable knock-out cell 
lines for industry. 
In this work, in order to aid in the discovery of new genes that are potential 
engineering targets for improved production of biopharmaceuticals in mammalian 
expression system, a HEK293 reporter cell line expressing luciferase reporter was subject 
to interference with 64,755 siRNAs targeting 21,585 human genes. 1,778 siRNAs 
strongly improved luciferase expression by having MAD-based z-core>3, which 
corresponded to 2.7% of the library. In order to exclude the ‘false positives’ introduced 
by off-target effects, gene hits were only considered ‘true positive’ if 2 or more single 
siRNAs targeting this gene passed the MAD-based z-core>3 requirement. 54 genes were 
selected with this stringent requirement and were subject to validation screen with 3 more 
siRNAs for each gene. Finally, data generated from 6 siRNAs for each of the 54 genes (3 
siRNAs from primary screen and 3 siRNAs from validation screen) were combined for 
the selection of top 10 genes. The gene is selected if 3 or more siRNAs yield >3 MAD-
based z-scores.  This high statistical significance also corresponds to biologically 
relevance, which is 40% increase in luciferase activity.  
To identify cellular functions or biological pathways correlated with improved 
luciferase expression, KEGG pathway analysis was done to discover important pathways 




were generated from the RSA analysis, a probability-based approach to circumvent off-
target effects by analyzing the collective behavior of all wells targeting the same 
gene[133]. While p <0.05 in RSA analysis indicates statistical significance of a single 
gene being distributed toward the top ranking slots, we chose a more stringent cutoff, p 
<0.005. Then, 362 genes (supplemental table.4.S2) were selected based on this criteria 
and were used for KEGG pathway analysis. Surprisingly, 28 out of 362 genes were 
involved in splicesome, a multimegadalton ribonucleoprotein (RNP) complex for pre-
mRNA splicing [134]. The 28 genes encode many important splicesome components 
such as splicing factors (sf3a3, sf3b2, sf3b3, sf3b4) and small nuclear ribonucleoproteins 
(snrnp200, snrpb, snrpd2, snrpd3, snrpe, snrpf, snrpg). This finding is counter-intuitive as 
the knock-down of these genes should theoretically compromise mRNA-splicing and 
could negatively regulate recombinant protein production.  
In good agreement with primary screen pathway analysis, splicesome was also 
highlighted by validation screen result (Table 4.1). Four (ints1, ints2, hnrnpc and prpf19) 
out of top ten genes were associated with splicesome pathway. Ints1 and ints2 encode 
two subunits of integrator complex, which indicates the involvement of this complex in 
influencing protein overexpression. Indeed, the integrator complex contains at least 12 
proteins in humans [135] and based on primary screen data, knocking down of ints1, 
ints2, ints3, ints4, ints5, ints8 and ints12 all resulted in significantly improved luciferase 
reporter expression (Supplemental Table.4.S3). Integrator complex mediates small 
nuclear RNAs (snRNAs) 3’ processing [135] and snRNAs are essential for the removal 
of introns, proper expression of histone mRNA and biosynthesis of ribosomal RNA[136]. 




The knocking-down of ints1, ints5, ints6, ints9 and ints11 has been reported. RNA 
interference of ints1, ints5 or ints11 resulted in the accumulation of misprocessed snRNA 
and ultimately splicing defects in pre-mRNAs for multiple genes [135, 137]. Ints6 is 
presumed to be tumor-suppressor gene as overexpression of ints6 in a prostate cancer 
cells reduces colony formation and causes a cell-cycle arrest[138]. RNAi-mediated 
down-regulation of ints11 leads to G1 arrest in human cells [139]. It is not clear why the 
down-regulation of integrator complex genes, which would presumably inhibit snRNA 
biosynthesis, leads to higher recombinant protein production. It could be resulted from 
splicing defects in specific genes, who are negative regulators of protein expression. 
Another possibility is that the depletion of integrator complex leads to growth arrest, thus 
allowing more energy and resources to be channeled to protein production process [85, 
112].  
The other two genes in splicesome pathway are hnrnpc and prpf19. They encode 
Heterogeneous Nuclear Ribonucleoprotein C (C1/C2) and Pre-mRNA Processing Factor 
19 respectively and are both associated with pre-mRNA splicing. Heterogeneous Nuclear 
Ribonucleoprotein C is a core component of heterogeneous nuclear ribonucleoproteins 
(hnRNPs) and is one of the most abundant proteins in the nucleus[140]. It’s well known 
that it’s involved in alternative splicing of pre-mRNA[141] and stabilization of 
mRNA[142]. However, its exact role in splicing regulation remained contradictory and 
unresolved[143]. Pre-mRNA Processing Factor 19 is a component of the prp19p-
associated complex (or NTC), which activates splicesome for pre-mRNA splicing [144]. 
It is also found to be essential for cell survival and damage DNA repair [145]. Prpf19 up-




depletion led to reduced resistance to apoptosis [146, 147]. In our luciferase primary and 
validation screen, the siRNA-mediated knocking-down of prpf19 gene didn’t lead to 
significant cell death. 
The rest of top genes encode proteins covering a wide range of biological 
functions.  
Casp8ap2 encodes caspase 8 associated protein 2, which is highly similar to the 
mouse apoptotic protein FLASH. It is shown to regulate caspase 8-induced activation of 
NF-kappa-B and it’s required for S-phase progression and histone gene transcription 
[148, 149].  
Oaz1 encodes ornithine decarboxylase antizyme 1, which down-regulates cellular 
polyamine level by binding to and inhibiting ornithine decarboxylase [150]. This gene 
will be investigated in detail in the next chapter.  
Ppp2r1a encodes an alpha isoform of the constant regulatory subunit A (PR 65) 
of protein phosphatase 2A(PP2A) and it serves as a scaffolding molecule[151]. PP2A is 
an important regulator in cell proliferation, signal transduction and apoptosis and it is 
implicated in the negative control of cell growth and division [152].   
Chaf1a encodes subunit A of chromatin assembly factor 1 (CAF-1), which 
assembles histone octamers onto replicating DNA [153]. CAF-1 is a histone chaperone 
that plays important roles in chromatin restoration after DNA synthesis, cell cycle 
progression, heterochromatin maintenance and asymmetric cell division[154].  
Cct2 encodes beta subunit of cytosolic chaperonin-containing t-complex 
polypeptide-1(CCT), which is a molecular chaperone important for folding of actin, 




associated with growth arrest and perturbation of actin-based cell motility in mammalian 
cells and it is believed to be required for cell cycle progression and cytoskeletal 
organization[156].  
Eef1b2 encodes beta subunit of eukaryotic translation elongation factor 1. The 
protein is a guanine nucleotide exchange factor involved in recruitment of aminoacyl- 
tRNAs onto the ribosome, which is the first step of elongation[157]. 
To test the effect of silencing top genes for expression of other proteins, one 
secreted protein(GPC3-hFc)  and two hard-to-express membrane proteins (neurotensin 
receptor type I and serotonin transporter) were investigated. For each cell line, at least 6 
out of 10 siRNAs tested improved the recombinant protein production. Notably, 4 genes 
were always improving protein production in all three cell lines: ints1, hnrhpc, oaz1 and 
ppp2r1a. It is found that ints1 or hnrnpc depleted cells consistently have growth 
disadvantages (Fig. 4.3, viable cell number), indicating they could be essential genes. 
Indeed, targeted disruption of ints1 in mouse embryos results in growth arrest followed 
by apoptotic cell death[158]. Taken together, oaz1 gene was chosen for follow-up studies 
in the next chapter since its knock-down was associated with minimal cell growth 
disadvantage. 
 
Contributions from collaborators: 
Dr. Scott Martin contributed to conceiving and designing of RNAi screen experiments 





Figures and tables 
Fig. 4.1. Genome-wide human siRNA library screen with HEK-CMV-luc2-Hygro cell 
line. (A) Workflow of the screen; (B) Distribution of siRNA activity on improved overall 
luciferase expression; top hits (MAD-based z-score>3.0) are highlighted; (C) For each 
siRNA sample, the relative per cell luciferase yield is plotted against relative viable cell 
number. The 20% increase cutoffs are highlighted and they divide the entire population 







Fig.4.2. Illustration of splicesome pathway enriched with primary screen top hits. All 362 
genes significantly improved luciferase expression (p<0.005 in RSA analysis) were 
imported for KEGG pathway mapping. 28 genes were found in splicesome pathway and 
were highlighted in red or pink in the map. Red color indicates genes with p<0.001thus 








Fig.4.3. Test of top 10 siRNAs with (A) luciferase, (B) GPC3-hFc, (C) NTSR1-GFP and 
(D) SERT-GFP expressing HEK cell line. All protein expression was normalized to cells 
tranfectecd with the negative control (siN.C.). The experiment was performed twice with 
different passages of cells. For each biological sample, the measurement was done in 






Fig.4.4. Co-transfection of binary siRNA mixtures from top 10 siRNAs. HEK-CMV-
Luc2-Hygro cells were transfected with two of top 10 siRNAs, each with final 
concentration of 40nM. Luciferase level of cells transfected negative control 
siRNA(siN.C.) was set at 100 and all co-transfection result was normalized. Subscripts 
indicate SEM. The experiment was performed twice with different passages of cells. For 


















INTS1 Integrator Complex Subunit 1 172 4.55 3’- end processing of small nuclear RNAs U1 and U2  





Influencing pre-mRNA processing and other aspects 
of mRNA metabolism and transport 





Inhibiting ornithine decarboxylase and inactivating 
the polyamine uptake transporter 
PPP2R1A 
Protein Phosphatase 2, 
Regulatory Subunit A, Alpha 
153 3.56 
Serving as a scaffold for Protein Phosphatase 2 
assembly, essential for signal transduction pathways 
PRPF19 Pre-mRNA Processing Factor 19 147 3.27 Spliceosome assembly and activating pre-mRNA splicing 
CHAF1A 
Chromatin Assembly Factor 
1, Subunit A 
138 2.80 
mediating chromatin assembly in DNA replication 
and DNA repair 
CCT2 
Chaperonin Containing TCP1, 
Subunit 2 (Beta) 
126 2.23 
Chaperonin-mediated protein folding of actin, tubulin 
and other proteins 
EEF1B2 
Eukaryotic Translation 
Elongation Factor 1 Beta 2 
124 2.13 
exchanging GDP bound to EF-1-α to GTP during the 
transfer of aminoacylated tRNAs to the ribosome 
* 
All values are medians of result from 6 siRNAs(3 siRNAs in primary screen and 3 siRNAs in validation screen) targeting a top gene. 
† 




Table.4.S1. Effects of knocking down of top 10 genes with six different siRNAs from primary and validation screens. 
Gene SiRNA sequence 














GCAUGAGCAAACUCCUCCAtt 200.62 5.97   238.61 2.58   100.63 0.8 
GUUCAUCCAUAAGUACAUUtt 198.35 5.86   153.44 -1.1   83.13 -0.56 
GGGUUUGUCGCUGGUGCUUtt 197.22 5.8   120 -2.55   94.71 0.34 
AGAUCUUUGUCAAGGUGUAtt 147.69 3.31   199.36 4.75   96.26 0.46 
GCAGGUCCUCUAUACCGCAtt 127.12 2.27   208.24 5.13   105.93 1.21 
CGCCUCCAUCAACUUCAAGtt 74.22 -0.39   76.63 -0.56   96.85 0.5 
INTS2 
GCGUAUUUUGAGAGUACUUtt 235.6 7.73   185.52 0.28   94.32 0.31 
GCACCCGAAUUGUGGAAGAtt 176.86 4.78   156.98 -0.95   105.67 1.19 
GACAUUGGAUCAUACUAAAtt 164.94 4.18   165.71 -0.57   88.91 -0.11 
GCAGCUUAGGCAUAAACUUtt 164.78 4.17   249.79 6.92   108.47 1.4 
GGCGAAUGCUCCUGACUAAtt 163.08 4.08   167.38 3.36   103.89 1.05 
GCAUGGAUCCUGAUGUACAtt 115.82 1.71   151.92 2.7   69.89 -1.58 
HNRNPC 
GAUGAAGAAUGAUAAGUCAtt 177.94 4.83   184.2 0.23   96.6 0.48 
ACACUCUUGUGGUCAAGAAtt 168.09 4.33   227.74 2.11   73.81 -1.28 
GCAGGUGUGAAACGAUCUGtt 167.64 4.31   163.5 -0.67   91.28 0.07 
CAACGGGACUAUUAUGAUAtt 159.23 3.89   183.65 4.07   97.39 0.55 
GGCAAUCUCAUUUAGUUGAtt 149.57 3.4   156.71 2.9   95.45 0.39 
GGCAAUCUUUUCGAAGUAUtt 128.44 2.34   121.86 1.4   105.4 1.17 
CASP8AP2 
CCCUGUUCAUUAUAAGUCUtt 216.11 6.75   192.64 4.46   79.25 -0.86 
CCAACAAGGAAGACGAAAAtt 191.23 5.5   83.35 -0.27   67.32 -1.78 




GGAUAUUGGAGGCUAGUCAtt 141.57 3   272.68 4.05   89.68 -0.05 
GGCUCACUGGACAUAUACGtt 83.8 0.1   284.06 4.54   100.53 0.79 
GGCAACAUAUAAUGAUUUGtt 82.52 0.03   157.87 -0.91   100.45 0.78 
OAZ1 
CCGUAGACUCGCUCAUCUCtt 174.47 4.65   204.23 4.96   85.43 -0.38 
GCUAACUUAUUCUACUCCGtt 171.15 4.49   154.72 2.82   110.62 1.57 
GCCUUGCUCCGAACCUUCAtt 161.2 3.99   90.31 0.04   94.84 0.35 
GAUUAUCCUUGUACUUUGAtt 144.54 3.15   169.97 -0.39   101.9 0.89 
GGCUGAAUGUAACAGAGGAtt 127.7 2.3   141.84 -1.6   94.98 0.36 
GGGAAUAGUCAGAGGGAUCtt 92.81 0.55   134.45 -1.92   102.77 0.96 
PPP2R1A 
GGUCAAAGAGUUCUGUGAAtt 208.07 6.34   161.61 -0.75   103.63 1.03 
CUUCGACAGUACUUCCGGAtt 168.11 4.34   254.01 3.24   104.02 1.06 
GAACAGCUGGGAACCUUCAtt 154.04 3.63   157.24 -0.94   60.65 -2.3 
GGAGUUCUUUGAUGAGAAAtt 151.51 3.5   200.79 4.81   96.36 0.46 
GGCGGAACUUCGACAGUACtt 143.16 3.08   135.32 1.98   105.8 1.2 
GGACCCGAAGUGAGCUUCUtt 84.88 0.15   87.22 -0.1   97.31 0.54 
PRPF19 
GGUAAAGUCACUGAUCUUUtt 195.28 5.7   191.25 4.4   102.11 0.91 
GCUCAUCGACAUCAAAGUUtt 165 4.18   130.64 1.78   97.01 0.52 
GCGCAAGCUUAAGAACUUUtt 161.12 3.98   96.79 0.32   94.58 0.33 
GGUCACCAGCGUGGUGUUUtt 132.76 2.56   170.09 -0.38   101.62 0.87 
CAACUUUGAGGUAAAGUCAtt 128.76 2.36   170.35 -0.37   95.58 0.41 
GGCCAUACCAAGAAGGUCAtt 92.93 0.56   134.71 -1.91   96.01 0.44 
CHAF1A 
GCCUGAAUCUUGUCCCAAAtt 188.25 5.35   228.48 2.14   82.39 -0.62 
CGAAACUUGUCAACGGGAAtt 187.37 5.3   179.21 0.01   104.55 1.1 
GAAGAAGACUCUGUACUCAtt 143.57 3.1   215.85 1.59   66.51 -1.85 
CCGACUCAAUUCCUGUGUAtt 131.57 2.5   144.01 2.36   91.36 0.08 




GCCGAUGACAUGUCAGACGtt 67.27 -0.73   65.03 -1.06   103.44 1.01 
CCT2 
CAUUGGUGUUGACAAUCCAtt 161.46 4   98.81 0.4   85.05 -0.41 
GUUGCAAACUUAUCGAGGAtt 147.74 3.31   107.88 0.79   79.09 -0.87 
CUCUUAUGGUAACCAAUGAtt 146.72 3.26   77.6 -0.51   91.56 0.09 
GGGUUCAAGAUGAUGAAGUtt 105.94 1.21   189.85 0.47   107.22 1.31 
GGCAUGGACAAAAUUCUUCtt 103.66 1.09   186.79 0.34   96.09 0.44 
GGGAAGCAGAAUCUUUAAUtt 81.36 -0.03   160.25 -0.81   104.85 1.12 
EEF1B2 
GGAAGAACGUCUUGCACAAtt 156.47 3.75   149.19 2.58   85.47 -0.38 
AGAAAGCUUUGGGCAAAUAtt 151.19 3.48   92.16 0.12   75.57 -1.14 
GGAGUGAAGAAAGCUUUGGtt 144.92 3.17   84.55 -0.21   97.14 0.53 
GAUAAAGUUGGAACAGAUAtt 103.4 1.08   183.07 0.18   110.85 1.59 
GGAAGUGGAGCUACAGAUAtt 98.4 0.83   200.07 0.91   106.78 1.27 















RSA analysis  
p-value 
SNRPB 1 2.18E-12 
INTS2 2 3.79E-10 
HNRNPC 3 1.04E-08 
PPP2R1A 4 4.85E-08 
DKFZP586J0619 5 1.17E-07 
INTS1 6 1.17E-07 
U2AF1 7 6.96E-07 
SF3B3 8 1.33E-06 
SNRPF 9 1.51E-06 
PRPF19 10 1.69E-06 
OAZ1 11 2.27E-06 
SF3B4 12 2.32E-06 
SART1 13 5.35E-06 
CASP8AP2 14 6.01E-06 
SNRPD2 15 6.22E-06 
KAT5 16 2.05E-05 
LOC642861 17 4.62E-05 
CHAF1A 18 4.92E-05 
CNOT1 19 5.15E-05 
EEFSEC 20 6.22E-05 
RDBP 21 7.29E-05 
CCT7 22 7.77E-05 
CSNK2B 23 8.48E-05 
LOC391322 24 9.24E-05 
USPL1 25 9.82E-05 
LOC731069 26 1.02E-04 
SNRNP200 27 1.14E-04 
PNMA2 28 1.39E-04 
MZF1 29 1.45E-04 
CCT2 30 1.61E-04 
SNRPE 31 1.80E-04 
ACADVL 32 1.85E-04 
LOC389722 33 1.89E-04 
TCERG1 34 1.94E-04 
APOBEC3H 35 2.02E-04 
EEF1B2 36 2.07E-04 
STAT6 37 2.51E-04 
CSE1L 38 2.54E-04 
LOC728268 39 2.58E-04 
LOC119358 40 2.65E-04 
TYW3 41 2.77E-04 
LOC729227 42 3.13E-04 
CCT4 43 3.17E-04 
DNALI1 44 3.70E-04 
ALG3 45 4.16E-04 
ACAD8 46 4.55E-04 
C20orf165 47 4.62E-04 
TH1L 48 4.93E-04 
FERMT1 49 5.08E-04 
CDCA7 50 5.29E-04 




TEX13B 52 5.64E-04 
LOC340602 53 5.82E-04 
ACSF2 54 5.98E-04 
CYLD 55 6.06E-04 
LOC340113 56 6.11E-04 
LOC649259 57 6.33E-04 
KCNJ10 58 6.39E-04 
IFIT1L 59 6.39E-04 
C20orf106 60 6.47E-04 
EIF4A3 61 6.56E-04 
SNRPD3 62 6.59E-04 
ACTL6A 63 6.69E-04 
SNRPG 64 6.70E-04 
ODF2L 65 6.74E-04 
LOC729316 66 6.75E-04 
LOC727974 67 6.77E-04 
LOC645602 68 6.93E-04 
LOC728232 69 7.14E-04 
ARCN1 70 7.25E-04 
PSMD4 71 7.37E-04 
ZNF195 72 7.39E-04 
LOC441282 73 7.85E-04 
ZFAND2A 74 7.86E-04 
SF3A3 75 8.13E-04 
C22orf26 76 8.15E-04 
NFYA 77 8.32E-04 
FAM102A 78 8.48E-04 
DUSP26 79 8.90E-04 
LOC731312 80 9.24E-04 
MGRN1 81 9.31E-04 
LOC728310 82 9.64E-04 
MKL2 83 9.70E-04 
LOC652595 84 9.70E-04 
NLRC3 85 9.80E-04 
LOC728073 86 1.03E-03 
LOC731523 87 1.04E-03 
CNTF 88 1.06E-03 
TST 89 1.06E-03 
OR10P1 90 1.11E-03 
PCGF1 91 1.11E-03 
SNRPEL1 92 1.11E-03 
ANKRD6 93 1.15E-03 
FEZF1 94 1.18E-03 
STAB1 95 1.18E-03 
FLRT1 96 1.20E-03 
FLJ43582 97 1.21E-03 
PLRG1 98 1.24E-03 
RNF138 99 1.24E-03 
EFCAB4A 100 1.25E-03 
GPI 101 1.26E-03 
SNX9 102 1.29E-03 
RAB31 103 1.33E-03 
IL17REL 104 1.34E-03 




RPTN 106 1.38E-03 
FXR2 107 1.39E-03 
COPB2 108 1.39E-03 
LOC642656 109 1.40E-03 
KIAA0947 110 1.40E-03 
LOC641845 111 1.42E-03 
PPP1R13L 112 1.43E-03 
DMAP1 113 1.44E-03 
NUDT21 114 1.48E-03 
LOC728292 115 1.50E-03 
ZNF621 116 1.52E-03 
LOC728086 117 1.56E-03 
NRN1 118 1.57E-03 
KIAA0999 119 1.57E-03 
PPP2R4 120 1.57E-03 
MPHOSPH8 121 1.58E-03 
NTF3 122 1.60E-03 
LOC650689 123 1.61E-03 
LOC390956 124 1.62E-03 
TRIM72 125 1.66E-03 
PELI3 126 1.69E-03 
LOC729017 127 1.71E-03 
L3MBTL2 128 1.71E-03 
SP8 129 1.72E-03 
PRPF8 130 1.73E-03 
LOC653303 131 1.73E-03 
ISOC1 132 1.75E-03 
L3MBTL4 133 1.77E-03 
RNF7 134 1.80E-03 
LOC729658 135 1.80E-03 
DHX15 136 1.80E-03 
LOC641796 137 1.80E-03 
LOC643916 138 1.81E-03 
RGS8 139 1.85E-03 
RIF1 140 1.88E-03 
FLJ40039 141 1.89E-03 
LOC646823 142 1.89E-03 
GTF2A2 143 1.93E-03 
SNX33 144 1.94E-03 
NKX3-2 145 1.96E-03 
RAB1B 146 1.99E-03 
hCG_1817208 147 2.01E-03 
TMEM180 148 2.04E-03 
OR4K2 149 2.08E-03 
SUPT6H 150 2.08E-03 
MORC2 151 2.12E-03 
PDZD3 152 2.12E-03 
SMAD3 153 2.15E-03 
NMNAT2 154 2.15E-03 
METTL2B 155 2.17E-03 
C10orf91 156 2.17E-03 
FLJ36144 157 2.18E-03 
C11orf84 158 2.21E-03 




SCIN 160 2.22E-03 
SDHC 161 2.23E-03 
LOC728977 162 2.23E-03 
ICA1L 163 2.25E-03 
VAV2 164 2.26E-03 
DNAJB12 165 2.26E-03 
VSIG8 166 2.28E-03 
VARS 167 2.30E-03 
CCL23 168 2.30E-03 
ANKRD1 169 2.31E-03 
LOC286411 170 2.35E-03 
PAQR7 171 2.35E-03 
RBM22 172 2.35E-03 
TFCP2L1 173 2.35E-03 
LOC646463 174 2.36E-03 
NPAT 175 2.37E-03 
ZNF596 176 2.37E-03 
C12orf43 177 2.38E-03 
ZNF213 178 2.40E-03 
ZNF207 179 2.40E-03 
AMN 180 2.40E-03 
SLC4A1 181 2.44E-03 
C1orf140 182 2.45E-03 
SFRS7 183 2.45E-03 
OR4C13 184 2.49E-03 
CLEC4M 185 2.49E-03 
SULT2A1 186 2.49E-03 
UPF1 187 2.49E-03 
SCGB1D2 188 2.51E-03 
SNAPC5 189 2.52E-03 
G3BP1 190 2.53E-03 
MIZF 191 2.54E-03 
GPR109B 192 2.55E-03 
PLEKHA6 193 2.55E-03 
ZBTB39 194 2.58E-03 
WDR68 195 2.58E-03 
ZCWPW2 196 2.59E-03 
ZNF562 197 2.62E-03 
MFSD11 198 2.63E-03 
MUS81 199 2.63E-03 
LOC730259 200 2.64E-03 
POU5F1 201 2.65E-03 
TDRD10 202 2.66E-03 
CSPG5 203 2.66E-03 
CHD1L 204 2.68E-03 
KDELR2 205 2.72E-03 
TPM3 206 2.73E-03 
WHSC2 207 2.73E-03 
SFRS1 208 2.74E-03 
MARK2 209 2.77E-03 
C1orf146 210 2.77E-03 
MACROD1 211 2.78E-03 
OPN1SW 212 2.82E-03 




PPP6C 214 2.84E-03 
IL28B 215 2.84E-03 
ECHDC3 216 2.86E-03 
WNT2 217 2.89E-03 
YTHDF2 218 2.89E-03 
HES4 219 2.91E-03 
PNPLA6 220 2.91E-03 
VMO1 221 2.92E-03 
U2AF2 222 2.95E-03 
RABGAP1L 223 2.98E-03 
ITPRIPL1 224 3.02E-03 
ALDH3A2 225 3.03E-03 
C20orf144 226 3.05E-03 
LOC730203 227 3.06E-03 
LOC401577 228 3.08E-03 
CDC20B 229 3.09E-03 
LOC646051 230 3.10E-03 
TNFRSF13C 231 3.11E-03 
SULT1A2 232 3.13E-03 
GSTZ1 233 3.13E-03 
DKFZp781N1041 234 3.13E-03 
LOC729619 235 3.14E-03 
WFDC2 236 3.14E-03 
LOC727874 237 3.15E-03 
LOC644093 238 3.18E-03 
TNF 239 3.19E-03 
SPRR3 240 3.20E-03 
FAM122B 241 3.23E-03 
LOC647591 242 3.23E-03 
TACC2 243 3.26E-03 
KRT71 244 3.26E-03 
TBP 245 3.27E-03 
INTS3 246 3.27E-03 
C14orf80 247 3.28E-03 
KCNE4 248 3.28E-03 
LOC731292 249 3.31E-03 
CMIP 250 3.31E-03 
ZNF519 251 3.32E-03 
HNRPDL 252 3.33E-03 
ISY1 253 3.34E-03 
CRYBA2 254 3.35E-03 
4-Sep 255 3.35E-03 
SF3B2 256 3.35E-03 
LOC644403 257 3.37E-03 
LOC728677 258 3.37E-03 
ABCB8 259 3.37E-03 
HOXC13 260 3.41E-03 
LOC644961 261 3.42E-03 
FOXN1 262 3.42E-03 
INTS8 263 3.45E-03 
LOC645914 264 3.46E-03 
BEST4 265 3.46E-03 
LOC729904 266 3.51E-03 




GPR162 268 3.55E-03 
C7orf62 269 3.57E-03 
USP49 270 3.60E-03 
UPK1B 271 3.60E-03 
FLJ30403 272 3.64E-03 
MRPL24 273 3.65E-03 
HSPE1 274 3.67E-03 
ACTA1 275 3.67E-03 
KPNB1 276 3.67E-03 
AP3M2 277 3.69E-03 
CCDC132 278 3.71E-03 
3-Mar 279 3.74E-03 
TRAF4 280 3.78E-03 
NHP2 281 3.78E-03 
BRP44L 282 3.79E-03 
VAV1 283 3.80E-03 
LOC732312 284 3.83E-03 
CHAT 285 3.88E-03 
SAMD11 286 3.88E-03 
PMVK 287 3.90E-03 
ZNF780B 288 3.92E-03 
hCG_1657980 289 3.92E-03 
PEPD 290 3.93E-03 
CHAF1B 291 3.94E-03 
CES7 292 3.97E-03 
ADRBK2 293 3.97E-03 
LOC647855 294 3.98E-03 
LOC653458 295 4.01E-03 
SLC16A12 296 4.02E-03 
FLJ44653 297 4.04E-03 
SLC15A5 298 4.06E-03 
MGC39606 299 4.07E-03 
KCNE3 300 4.10E-03 
DDOST 301 4.11E-03 
PIP5K1A 302 4.11E-03 
LOC643749 303 4.12E-03 
COBRA1 304 4.12E-03 
C1orf114 305 4.15E-03 
ANKRD28 306 4.15E-03 
NRXN3 307 4.16E-03 
MEGF11 308 4.18E-03 
RBM8A 309 4.18E-03 
TSPAN14 310 4.20E-03 
C17orf80 311 4.20E-03 
ASF1A 312 4.25E-03 
FLJ11286 313 4.29E-03 
MS4A4E 314 4.30E-03 
LOC644592 315 4.31E-03 
MGC42105 316 4.33E-03 
NUCKS1 317 4.34E-03 
ZNF709 318 4.34E-03 
PROM2 319 4.35E-03 
PABPC1 320 4.36E-03 




SMAP2 322 4.38E-03 
ROMO1 323 4.38E-03 
KCTD15 324 4.39E-03 
WBP11 325 4.41E-03 
ADORA2A 326 4.42E-03 
LOC645852 327 4.43E-03 
TTC19 328 4.44E-03 
SLC11A1 329 4.46E-03 
COPA 330 4.52E-03 
CD79A 331 4.53E-03 
GEMIN8 332 4.53E-03 
LOC387927 333 4.55E-03 
LOC158376 334 4.57E-03 
CTBP1 335 4.61E-03 
TMEM174 336 4.61E-03 
GDPD3 337 4.66E-03 
UBE2NL 338 4.67E-03 
PPP2CA 339 4.69E-03 
LOC389365 340 4.71E-03 
TCEAL4 341 4.71E-03 
TLN1 342 4.74E-03 
LOC138652 343 4.76E-03 
ERMP1 344 4.77E-03 
JTV1 345 4.77E-03 
EP400 346 4.78E-03 
OCRL 347 4.79E-03 
SLC25A18 348 4.80E-03 
COL29A1 349 4.80E-03 
NRAP 350 4.81E-03 
DCP1A 351 4.82E-03 
NEURL2 352 4.84E-03 
THRA 353 4.85E-03 
UNC45A 354 4.88E-03 
LOC388553 355 4.89E-03 
MGC16121 356 4.89E-03 
ZNF534 357 4.91E-03 
LOC728030 358 4.91E-03 
RBM39 359 4.91E-03 
LOC729594 360 4.94E-03 
LOC642277 361 4.97E-03 




Table.4.S3. Summary of knocking down of different integrator complex subunits  
Gene  SiRNA sequence 
Overall luciferase yield   Viable cell number 




GCAUGAGCAAACUCCUCCAtt 200.62 5.97   100.63 0.8 
GUUCAUCCAUAAGUACAUUtt 198.35 5.86   83.13 -0.56 
GGGUUUGUCGCUGGUGCUUtt 197.22 5.8   94.71 0.34 
AGAUCUUUGUCAAGGUGUAtt 147.69 3.31   96.26 0.46 
GCAGGUCCUCUAUACCGCAtt 127.12 2.27   105.93 1.21 
CGCCUCCAUCAACUUCAAGtt 74.22 -0.39   96.85 0.5 
INTS2 
GCGUAUUUUGAGAGUACUUtt 235.6 7.73   94.32 0.31 
GCACCCGAAUUGUGGAAGAtt 176.86 4.78   105.67 1.19 
GACAUUGGAUCAUACUAAAtt 164.94 4.18   88.91 -0.11 
GCAGCUUAGGCAUAAACUUtt 164.78 4.17   108.47 1.4 
GGCGAAUGCUCCUGACUAAtt 163.08 4.08   103.89 1.05 
GCAUGGAUCCUGAUGUACAtt 115.82 1.71   69.89 -1.58 
INTS3 
GAGUUGCUAUGACAAUGCAtt 123.34 2.08   89.05 -0.1 
GGUGCGAUUUGGUCAACAAtt 118.51 1.84   93.06 0.2 
CCUGGUUAUGUUUCGAAAAtt 106.78 1.25   108.42 1.39 
INTS4 
CUAUCUUCGCUGUCAACUAtt 134.61 2.65   82.06 -0.64 
CAGCGAAACAGAUUAUGGAtt 126.76 2.25   84.39 -0.46 
CGUCUCAUGGUGUAAGAAAtt 73.11 -0.44   72.38 -1.39 
INTS5 
GGAGGGAUUUGGUCAGUUUtt 137.68 2.8   96.29 0.46 
GGUGCAUGCAGGGACAUUAtt 113.5 1.58   92.51 0.16 
GUACAUUAAUGGACAUCUAtt 91.86 0.5   87.47 -0.22 
INTS6 
UGCUGGUCACUUUCGAAGAtt 97.63 0.79   106.46 1.24 
GGCUGAAGGACUUACGACUtt 94.78 0.64   105.68 1.18 
GGACAGCUUUUGAUUUAUUtt 85.27 0.17   93.2 0.22 




CCAGGACUCUUCCGCAAAAtt 110.06 1.41   109.63 1.49 
CCAGUAGACUUGAAGCUAAtt 88.21 0.31   89.3 0 
INTS8 
CCAUAGAUGAGAAGCGGUUtt 188.15 5.34   93.47 0.24 
CCACUCGUUUUGACUAUUAtt 136.39 2.74   91.32 0.075 
GACCAGGUAAUAAAACGAAtt 95.02 0.66   89.19 -0.08 
INTS9 
GGAUCAUCCAGUCUCAUUAtt 115.21 1.67   95.94 0.43 
CAUGCAAUGUGCUCAAAUUtt 106.67 1.24   68.11 -1.72 
GCAAAGUCCUGAAGCCUUUtt 84.71 0.14   76.16 -1.09 
INTS10 
GGAGGAACCCUCGAAAGUAtt 100.32 0.92   94.1 0.29 
GGAGAUAUUUUGCAUAGAAtt 96.92 0.75   85.37 -0.38 
CAACCAUGAUGUUCGAUUAtt 94.63 0.64   114.27 1.85 
INTS12 
GUAGCAAGGAUUUACCUAUtt 116.43 1.73   98.09 0.59 
CCUCUAACCUUGGGUAAAAtt 112.69 1.54   98.82 0.66 




Chapter 5: knockdown of ornithine decarboxylase antizyme1 causes increased 
polyamine accumulation and improved luciferase translation in HEK293 cells 
 
Abbreviations used: 
ODC, ornithine decarboxylase; OAZ, ornithine decarboxylase antizyme; AZI, antizyme 
inhibitor; HEK, human embryonic kidney; CMV, cytomegalusvirus; DMEM, Dulbecco’s 
modified Eagle’s medium; FBS, fetal bovine serum; PBS, phosphate-buffered saline; 
TCA, trichloroacetic acid; EDTA, ethylenediaminetetraacetic acid; DMFO, 
difluoromethylornithine. 
 
5.1 - Summary  
Polyamines are essential molecules intimately involved in the regulation of cell 
proliferation, transformation and tumorigenesis and their homeostasis is tightly 
maintained at multiple levels.  Ornithine decarboxylase (ODC) is the rate-limiting 
enzyme in polyamine biosynthesis and is probably the most highly regulated protein in 
mammalian cells. Oaz1 gene encodes ODC antizyme, a major negative regulator of ODC 
and polyamines. In this chapter, we investigated the mechanisms why luciferase 
expression is enhanced in antizyme depleted cells. By comparing ODC, antizyme and 
cellular polyamines concentrations between oaz1-knockdown and negative control cells, 
it is found that when antizyme was depleted, ODC enzyme and cellular polyamines levels 





5.2 - Introduction   
Polyamines (putrescine, spermidine, and spermine) are essential polycations that 
affect many biochemical processes [159, 160]. They interact with negatively charged 
molecules such as DNA, RNA, protein and phospholipids [160, 161], exerting a wide 
range of effects on replication, transcription, translation and post-translational 
modification processes as well as on membrane stability[161]. Even though the exact 
physiological functions and the precise mechanisms of polyamines in mammalian cells 
have remained unclear, it has been shown that polyamines are largely involved in 
regulation of cellular proliferation, transformation, differentiation, apoptosis, and 
tumorigenesis [162, 163]. Elevated polyamine accumulation has been associated with cell 
proliferation and transformation while decreased polyamines level inhibits cellular 
growth, migration, and embryonic development [164]. As dysregulation of cellular 
polyamine is associated with various cancer pathology, polyamine pathways have been 
explored intensively as targets for cancer chemotherapy and chemoprevention[163, 165].  
Ornithine decarboxylase (ODC), spermidine synthase and spermine synthase are 
three major enzymes in the polyamine biosynthesis pathway and ODC is the first and 
rate-limiting enzyme (Fig.5.S1 ). Firstly, ornithine is decarboxylated by ODC to form 
putrescine. Then, catalyzed by spermidine synthase, putrescine receives the amino 
propylic group from decarboxylated s-adenosylmethionine (dcSAM) to form spermidine. 





Cellular polyamines are highly regulated by antizyme (OAZ) and antizyme 
inhibitor (AZI)-mediated regulation of ODC (Fig.5.S2). Antizymes are naturally 
occurring negative regulators of ODC[166]. They can inhibit ODC activity by forming 
heterodimers with ODC [167] and can lead to fast ubiquitination –independent ODC 
degradation by 26S proteasome[168]. ODC has a half-life of one to two hours in the 
absence of antizyme and the presence of antizyme reduces the half-life to minutes [169]. 
Antizyme levels are very low in most tissues [170],  but they are rapidly increased in 
response to elevating polyamine levels via a mechanism that is not completely 
understood[171]. Antizyme inhibitors can inactivate antizyme by binding to antizymes 
with higher affinity than ODC, thus allowing release of ODC from antizyme inhibition. 
[172]. 
In humans, antizymes comprise of a family of at least 3 members[173]. Antizyme 
1 is distributed in all tissues. It promotes ODC degradation via the 26S proteasome [168], 
inhibits polyamine uptake into the cell and stimulates polyamine export [174, 175]. 
Mammalian antizyme 2 is also distributed in all tissues but is less abundantly expressed 
[176]. It lacks ODC degradation capability but can inhibit polyamine uptake [177]. 
Antizyme 3 is only expressed during spermatogenesis in testis tissues [178]. Antizyme 1 
is most intensively studied due to its effective regulation on cellular polyamine levels and 
it is directly referred to as “antizyme”. It has been shown that antizyme mRNA level does 
not change with cellular polyamine concentration[179]; but polyamine level influences 
antizyme expression on translational level. Elevated polyamine concentration induces a 
+1 ribosomal frameshift, which is needed for functional antizyme expression [180]. As a 




In chapter 4, we have identified oaz1 gene as a top candidate to knock-down for 
enhanced luciferase expression. As oaz1 gene encodes ODC antizyme 1, it is speculated 
that the oaz1 gene knock down may lead to elevated cellular ODC and polyamine 
concentrations, resulting in improved protein production. In this chapter, ODC, antizyme 
and cellular polyamines concentrations are compared between oaz1-knockdown and 
negative control cells. The results showed that in antizyme depleted cells, ODC enzyme 
and cellular polyamines levels were up-regulated, leading to enhanced luciferase 
translation.   
 
5.3 - Materials and Methods  
5.3.1. Cell culture and transfection 
Silencer siRNA for oaz1 gene (Catalog number: AM51331, assay ID: 46078) and 
Silencer Select Negative Control #2 were purchased from Life Technologies.  AllStars 
Hs Cell Death Control was purchased from Qiagen. HEK-CMV-Luc2-Hygro cells 
constitutively expressing P. pyralis luciferase (Progema) were grown in DMEM 
supplemented with 10% FBS in a humidified incubator set at 37ºC and 5% CO2. 
The transfection was done in 6-well plate format: 0.12 nmol of each siRNA was 
added to each well (Corning) and 1.5mL of serum-free DMEM containing 11.25 μL of 
Lipofectamine RNAiMax (Life Technologies) was then added to each well. This lipid-
siRNA mixture was incubated at ambient temperature for 30 min prior to adding 2×10
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incubatied at 37ºC in 5% CO2 and were harvested at 24hours, 48hours, 72 hours and 96 
hours.  Cells transfected with Silencer Select Negative Control siRNA were used for data 
normalization and cells transfected with AllStars Hs Cell Death Control siRNA was used 
as transfection efficiency control.  
5.3.2. Isolation of RNA and real-time qRT-PCR  
Cells were trypsinized from 6-well plates, washed with PBS twice and cell pellets 
were flash frozen on dry ice and then stored at -80˚C until extraction. RNA was extracted 
from the HEK-CMV-Luc2-Hygro cell pellet using the RNeasy kit (Qiagen) and then 
treated with DNase using TURBO DNA-free
TM
 Kit (life technologies). CDNA was 
generated from the RNA using the Maxima Frist Strand cDNA Synthesis Kit for qRT-
PCR (Thermo Scientific). The real-time qPCR was done using Fast SYBR® Green 
Master Mix (life technologies) in 7900 HT Fast Real Time PCR System (Applied 
Biosystems). The 2
-∆∆Ct 
method was used for relative expression analysis[181] with gapdh 
as reference gene. Cells transfected with negative control siRNA and harvested at 24hr 
was set as calibrator. Primer used for each gene: luc (Promega), 5’-
TCACGAAGGTGTACATGCTTTGG-3' and 5'-GATCCTCAACGTGCAAAAGAAGC-
3'; odc1, 5’-TAAAGGAACAGACGGGCTCT-3’ and 5’- 
CCATAGACGCCATCATTCAC-3’; oaz1: 5’- GGAACCGTAGACTCGCTCAT-3’ and 
5’-TCGGAGTGAGCGTTTATTTG-3’; gapdh: 5’- CATCAATGGAAATCCCATCA-3’ 
and 5’- TTCTCCATGGTGGTGAAGAC-3’.   




Overall luciferase activity was determined by ONE-Glo™ Reagent (Promega) and 
the number of viable cells was determined with CellTiter-Glo™ Reagent (Promega). 
Upon addition of assay reagent, all plates were incubated at room temperature for 20 
minutes to stabilize luminescent signal before reading with SpectraMax i3 plate reader 
(Molecular Devices).  Cells tranfected with Silencer Select Negative Control siRNA was 
used for normalization. Per cell luciferase production was calculated from overall 
luciferase activity and viable cell number. 
5.3.4. Western Blotting  
Transfected cells were lysed in buffer containing 50 mm Tris-HCl, pH 7.4, 5 mM 
EDTA, 150 mM NaCl, 1% Nonidet P-40, and protease inhibitor mixture. Proteins (∼20 
μg) were separated by SDS-PAGE (4–12% gel) in MES buffer and transferred to 0.2-μm 
nitrocellulose membrane for immunodetection using mouse anti-ODC (Sigma, catalog 
number O1136) and mouse anti-β-actin (BD biosciences, catalog number 612657) 
primary antibodies and HRP conjugated anti-mouse secondary antibodies (abCAM, 
catalog number ab20043). Signals were detected with an ECL Plus chemiluminescence 
reagent.  
5.3.5. Cellular polyamine concentration measurement 
Cells in six-well plates were washed with PBS twice, harvested, and precipitated 
with 0.1 mL cold 10% (vol/vol) trichloroacetic acid (TCA). A total of 50μL of the TCA 
supernatant was used for polyamine analysis by ion exchange chromatographic system as 




5.4 - Results  
5.4.1. Effective knocking-down of oaz1 gene with siRNA 
Of the three mammalian antizyme genes, oaz1, oaz2, and oaz3 encode three 
antizyme isoforms. We tested several siRNAs designed against three oaz genes 
(Supplemental Table 5.S1). Five of six oaz1 siRNA significantly enhanced luciferase 
expression. In contrast, none of the siRNAs against oaz2 or oaz3 caused an increase in 
luciferase expression, probably due to the fact that antizyme 2 is a minor form and that 
antizyme 3 is expressed only in testis.  
Among the six siRNAs targeting oaz1 gene, one was chosen for further studies 
(siOAZ1: GCUAACUUAUUCUACUCCGtt), as it caused significant increase in 
luciferase without reducing cell viability. In order to examine the efficacies of antizyme 1 
knockdown using siOAZ1, qRT-PCR was executed to determine oaz1 mRNA level (Fig. 
5.1). In the first 72 hours, the relative expression of oaz1 mRNA was less than 3% upon 
siRNA transfection compare to negative control siRNA transfected cells, confirming 
good silencing effect of the siRNA. The 96 hour sample showed 7% relative expression 
level. 
5.4.2. The improved luciferase expression is not due to improved transcription of luc 
gene 
To investigate if the enhanced luciferase expression is resulted from transcription 
or translation step, the mRNA level of luc gene was also determined. While cells 




their luc mRNA levels remained consistently comparable to negative control cells 
throughout the 96 hour period (Fig. 5.2B). In addition, there is significant cell growth 
improvement in the first 48 hours upon siOAZ1 transfection (Fig. 5.2A). 
5.4.3. Ornithine decarboxylase is over-expressed in oaz1-depleted cells 
As antizyme 1 inhibit ornithine decarboxylase (ODC) and render it for 
degradation, ODC protein and mRNA levels in siOAZ- and siN.C.- transfected cells were 
also determined.  Western blot showed limited ODC enzyme level in un-transfected and 
siN.C. transfected cells. Upon silencing of oaz1 gene, ODC level was significantly 
elevated, from 48 to 96 hours post siOAZ1transfection (Fig. 5.3A). However, the 
elevated ODC protein level is not due to enhanced odc1 gene transcription. To the 
contrary, qRT-PCR demonstrated consistent reduction of odc1 mRNA levels after 
silencing of oaz1 gene (Fig. 5.3B). 
5.4.4. Cellular putrescine concentration is highly up-regulated in oaz1-depleted cells 
To investigate if the knocking-down of oaz1 gene influence cellular polyamine 
concentration, the levels of three major polyamines, putriscine, spermidine and spermine 
were determined in siOAZ1- and siN.C- transfected cells. As shown in Fig.5.4, 
polyamines concentrations were normalized with total protein and presented as nmol/mg 
total protein. In oaz1-depleted cells, putriscine concentration is 10 fold as high as that in 
negative control cells.  Spermidine concentration was also up-regulated, but to a lesser 
degree of up to one-fold increase in the first 72 hours. Spermine, the last product down 




5.4.5. Exogenous addition of polyamine into culture media improves luciferase 
expression 
To further verify whether elevated polyamine concentration can lead to improved 
luciferase expression, different titers of putriscine, spermidine and spermine were 
independently added into cell culture media and their impacts on luciferase expression 
level and viable cell number were determined. With putrescine addition, up to 40% 
increase of luciferase expression was observed (at 100µM) and the cell growth was 
enhanced up to 10% (at 50 µM). Higher concentrations could not generate further 
improvements (Fig.5.5.A).  For spermidine addition, the best effects were reached at a 
lower titer: a 36% increase in luciferase expression was obtained at 20 µM spermidine 
while a 24% increase in cell growth was achieved with 10 µM spermidine.  In addition, 
reduction in both luciferase expression and viable cell number were observed with >100 
µM spermidine (Fig.5.5.B).  The addition of spermine is not beneficial when the titer is 
>20 µM.  At a lower concentration (10 µM), a 16% increase in luciferase expression was 
observed (Fig. 5.5.C). 
 
5.5 - Discussion  
In chapter 4, we identified oaz1 gene encoding ornithine decarboxylase antizyme 
1 to be a promising target for detailed investigation, as the siRNA-mediated knocking-
down of oaz1 gene can consistently improve expression of multiple model proteins 
without significantly reducing cell viability. This provides highlights on the importance 




Polyamines are essential molecules, intimately involved in the regulation of cell 
proliferation, transformation and tumorigenesis [183].  Dysregulation of polyamine 
metabolism has been implicated in the pathogenicity of several human diseases, including 
cancer [183]. As polycations, they specifically bind to nucleic acids, proteins and 
phospholipids and regulate the stability, synthesis and activities of the macromolecules 
[150, 161, 184]. The most critical cellular function of polyamines appears to be the 
promotion of translation, because depletion of cellular spermidine and spermine by 
overexpression of a key polyamine catabolic enzyme, spermidine/spermine N1-
acetyltransferase 1 (SSAT1) leads to a total suppression of protein synthesis without 
inhibition of synthesis of DNA and RNA [185]. The current data also suggest that, in a 
reciprocal situation, increased cellular polyamines can enhance reporter protein synthesis 
without increasing their transcription. In spite of abundant evidence for the critical 
function of polyamines, ODC and antizyme in cellular transformation and proliferation 
[186-188], their mechanism of action and the sequence of events are poorly understood at 
the molecular level.  
In this chapter, we firstly examined the efficacies of antizyme 1 knockdown using 
siOAZ1. It is confirmed from real time qPCR results that this siRNA effectively down-
regulated oaz1 mRNA by 97% and the depletion extended to 96 hours post transfection 
(Fig. 5.2A). Upon antizyme depletion, luciferase expression was significantly improved 
from 48hrs to 96hrs but luciferase mRNA levels were slightly reduced compared to cells 
transfected with non-complementary siRNA (siN.C.). This finding indicates that the 




luciferase gene and that antizyme depletion enhanced luciferase expression at the level of 
translation.  
As expected from the known function of antizyme in down-regulation of ODC by 
inducing its proteosomal degradation, ODC enzyme level was found increased in 
antizyme-depleted cells (Fig.5.3A). As a highly regulated protein with an extremely short 
half-life, ODC level fluctuates depending on cellular proliferative status, cellular 
polyamine level and external stimulus. The significantly higher ODC level in oaz1 
knockdown cells indicates the stabilization of ODC protein upon depletion of antizyme 1. 
Interestingly, ODC mRNA levels were significantly reduced upon siOAZ1 tranfection in 
a time-dependent manner.  Judging from the nucleotide sequence of ODC mRNA, 
siOAZ1 is not predicted to bind to ODC mRNA to cause its degradation. Thus a decrease 
in ODC mRNA may be an indirect effect of oaz1 knockdown. 
Consistent with the ODC enzyme level, cellular putrescine level was sharply 
increased by 24 hrs of transfection with siOAZ1. Spermidine level also increased, but 
spermine level was lower than in the control siRNA-transfected cells. The sum of three 
polyamines was higher in OAZ1 knockdown cells, mainly due to a large increase in 
putrescine.  
It has been reported that addition of polyamines in serum free medium increased 
production of recombinant proteins in mammalian cells [189] and polyamines can be 
included as components of commercial serum-free medium used for recombinant protein 
production.  Our data is in accordance with these findings. It was found that exogenous 




to 10% increase of cell growth. The best effects with spermidine and spermine were 
observed at a much lower titer, 20 µM and 10 µM respectively. Higher concentration led 
to significant proliferation inhibition, probably due to ruminant plasma amine oxidase 
which generates toxic acrolein[190]. 
Taken together, our studies suggest that in oaz1 knocking-down cells, ODC 
enzyme and cellular polyamines levels were found to be up-regulated, leading to 
enhanced translation of luciferase and other reporter proteins. This is the first report to 
our knowledge to have improved recombinant protein production by engineering ODC 
enzyme or its antizyme.  
ODC and antizymes were mostly investigated for their impact on cell 
proliferation and transformation, especially in cancer research. For example, 
overexpression of ODC caused enhancement of proliferation and transformation of 
immortalized mouse fibroblasts NIH3T3 cells [191, 192]. In transgenic mice 
overexpressing ODC under a keratin promoter, tumor incidence increased after a variety 
of stimuli, including chemical carcinogens, UV radiation, and an activated Ras, whereas 
treatment with ODC inhibitor difluoromethylornithine (DFMO) prevented tumor 
development [193, 194] . In contrast to ODC, lots of research confirmed the anti-
proliferative effect of antizyme 1 and suggest a role for antizyme as a potential tumor 
suppressor[195]. For example, in several human oral cancer cell lines, the expression 
level of the oaz1 gene was down-regulated [196, 197]. Overexpression of antizyme in 
different cell culture models abolishes ODC activity, suppresses cellular levels of 




apoptosis [164, 198-201]. In vivo, overexpression of an oaz1 mutant clone under a keratin 
promoter reduced tumor formation in mouse skin, suggesting its tumor suppressive 
effects [202].  
In addition to inhibition of ODC, antizymes also inhibit transport/uptake of 
polyamines [174, 203]. Since ODC and antizyme have opposite effects on polyamine 
levels, they would have opposite effects on reporter gene expression. Indeed, ODC 
siRNA reduced expression of luciferase (Supplemental Table 5.S2). In this regard, it 
would be interesting to determine whether overexpression of ODC would stimulate 
reporter protein production as antizyme knockdown does. This will provide interesting 
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Figures and tables 
Fig. 5.S1. Biosynthetic pathway of polyamines (putrescine, spermidine and spermine). 






Fig.5.S2. Schematic diagram showing antizyme (OAZ) and antizyme inhibitor (AZI)-
mediated regulation of ornithine decarboxylase (ODC). Figure adapted from reference 










Fig. 5.1.  Relative expression of oaz1 gene in cells transfected with siRNA targeting oaz1 
(siOAZ1) and in cells transfected with negative control siRNA (siN.C.). The relative 
changes in genes expression were compared at 24, 48, 72 and 96 hours. Transfection was 
done with two different passages of cells and each biological sample was measured in 







Fig. 5.2.  Luciferase protein expression was enhanced (A) but not the relative 
transcription of luc gene (B) in antizyme depleted cells. The relative changes in luciferase 
protein/gene expression and viable cell number were compared to cells transfected with 
negative control siRNA (siN.C.). Transfection was done with two different passages of 






Fig. 5.3.  Elevated ODC enzyme concentration (A) and reduced odc mRNA level (B) 
were detected in cells transfected with siOAZ1. Transfection was done with two different 












Fig. 5.4. Cellular (A) putrescine, (B) spermidine and (C) spermine concentration in oaz1 
depleted and negative control cells. Polyamines concentrations were normalized with 







Fig. 5.5. The effect of exogenous addition of polyamines on luciferase expression and 
cell growth. Polyamine addition was done with two different passages of cells and each 





Table.5.S1. The effects of antizyme genes knocking-down with different siRNAs. 






oaz1 GCCUUGCUCCGAACCUUCAtt 161.2 94.8 
oaz1 GAUUAUCCUUGUACUUUGAtt 144.5 101.9 
oaz1 GGCUGAAUGUAACAGAGGAtt 127.7 95.0 
oaz1 CCGUAGACUCGCUCAUCUCtt 174.5 85.4 
oaz1 GCUAACUUAUUCUACUCCGtt 171.1 110.6 
oaz1 GGGAAUAGUCAGAGGGAUCtt 92.8 102.8 
oaz2 ACAUCGUCCACUUCCAGUAtt 97.4 96.3 
oaz2 GGACCUCCCUGUGAAUGAUtt 95.4 86.0 
oaz2 CAGAUGGAUUAUUAGCUGAtt 94.9 105.4 
oaz3 CCGGGAAAGUUUGACUGCAtt 101.6 75.8 
oaz3 CCACGACCAGCUUAAAGAAtt 90.5 95.8 
oaz3 GACUUUCACUUCCGCCUUAtt 74.3 87.7 
*values are normalized with cells transfected with negative control siRNA (siN.C.) . The 
















Viable cell density 
(%)* 
GCUUGCAGUUAAUAUCAUUtt 28.4 60.8 
GCAUGUAUCUGCUUGAUAUtt 20.0 50.7 
GAUGACUUUUGAUAGUGAAtt 18.0 56.1 





Chapter 6: Conclusion and future work 
6.1 – Final Remarks 
The goal of this study is to develop strategies to improve the functional 
expression of mammalian membrane proteins. Neurotensin receptor type I (NTSR1) was 
utilized as a model protein, as it’s a hard-to-express G protein-coupled receptor (GPCR) 
and its structure was not solved. We proposed that by engineering of the host organism 
and production process, we would be able to produce adequate amounts of purified 
receptors, to aid the crystallography studies of NTSR1. In addition, the successful 
strategies can be transferred to improving the production of other difficult proteins. 
This dissertation demonstrated three effective strategies, including the adoption of 
mammalian inducible expression system, production process development and high-
throughput RNA interference screening. 
The utilization of human embryonic kidney (HEK) cell line harnessed the near-
native environment of mammalian cells for protein translation, modification, folding and 
trafficking, thus contributed to the ideal quality of the membrane proteins produced. The 
adoption of the tetracycline inducible system allowed the external switching-on of protein 
production process, making it possible to manipulate temporally the event of cell growth 
and toxic protein production. This first strategy remarkably improved NTSR1 production 
comparing to constitutive expression approach.  
The process development strategy in this dissertation included suspension culture 




of this strategy is fine-tuning of the production procedures to push the NTSR1 production 
to the extent of host organism’s limit.  
Once the host organism’s capacity has been reached, further cell line engineering 
will be necessary to expand the host organism’s limit. This dissertation focused on a 
bottom-up high throughput screening approach, to prove that this strategy can efficiently 
enhance membrane protein production and can lead to identification of limiting factors 
that need to be reserve-engineered. 
Indeed, the polyamine studies in chapter 5 served as a proof of concept that the 
genome-scale loss-of-function data is valuable for understanding the protein expression 
process and can lead to exciting findings and applications. For example, even though the 
polyamine biosynthesis pathway and its regulation have been studied for decades, there 
were no reports on engineering any factors in this pathway for the purpose of enhancing 
protein production. The screen result shed light on this pathway, leading to targeted 
investigation followed  by fast and efficient application of pre-existing biological 
research results. 
  
6.2 – Future work 
Continuation and expansion of the work detailed in this dissertation is currently 
underway. Firstly, five miRNAs (hsa-miR-22-5p, hsa-miR-18a-5p, hsa-miR-22-3p, hsa-
miR-429 and hsa-miR-2110) have been identified in chapter 3 and the identification of 




data, it will contribute to our understanding of the mechanism behind improvement of 
protein expression. Secondly, a HEK293 cell line stably over-expresing hsa-miR-22 is 
being constructed and tested.  This experiment will allow us to investigate stable 
inhibition and combinatorial effects of miRNAs (hsa-miR-22 is composed of hsa-miR-
22-5p and hsa-miR-22-3p arms). Thirdly, CRISPR cell lines knocking out each of 
identified top 10 genes (ints1, ints2, hnrnpc, casp8ap2, oaz1, ppp2r1a, prpf19, cct2, 
chaf1a, eef1b2) will be constructed to investigate if the gene deletion can intensify the 
effects. This will also serve as a proof of concept for instustrial application of screen hits. 
Finally, as discussed in chapter 5, as ODC and antizyme has opposite effects in cellular 
polyamine concentration, it would be interesting to determine whether overexpression of 
ODC would stimulate reporter protein production as antizyme knockdown does. The 
comparison of the two system is especially interesting because antizyme not only inhibit 
ODC but also regulate polyamine trasport /updake. 
In addition, there are many more interesting project candidates derived from this 
study.  
First of all,  as large-scale transient gene expression with HEK293 cells has been 
widely applied in contract manufacturing organizations (CMO) for fast preparation of 
secreted medical proteins, is it possible to establish a similar strategy for membrane 
protein production? Such expression strategy will greatly benefit crystallography society 
as it will generate correctly-folded proteins while keeping a fast turn-over rate.  
Secondly, as all of the work in this dissertation is based on loss-of-function 
studies, our dataset is not complete. It will be very interesting to carry out gain-of-




With a two-sided story, we will be able to understand better the positive or negative 
involvment of different genes in protein biosynthesis and cell growth.  
Thirdly, from production point of view, it will be more beneficial to execute 
genome-scale siRNA screen with Chinese Hamster Ovary cells (CHO). Since the hamster 
siRNA library is still lacking, murine library could be used instead. Or top hits from this 
HEK293 screen can be tested with CHO cells. 
Additionally, the splicesome pathway has been high-lighted in chapter 4 and the 
clear involvment of integrator complex is very intriguing. It’ll be worthwhile to look into 
luciferase mRNA level upon the transfection of these siRNAs, to investigate if the altered 
splicesome pathway changed luciferase transcription level. Specifically for integrator 
complex, it’ll be interesting to check U1/U2 snRNA level. 
Apart from genes involved in mRNA splicing process and polyamine pathway, 
there are many others worth further investigation(casp8ap2, ppp2r1a, cct2, chaf1a, 
eef1b2) for mechanistic studies. The knocking down of ppp2r1a for example, can 
enhance the expression of cytosolic, secreted and membrane proteins tested, and also 
introduced minimal cell growth disadvantage. As an important serine/threonine 
phosphatase with diverse cellular functions, protein phosphatase 2 (PP2) has been 
intensively studied for years. It will be interesting to deciper how this global regulator 
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Education 
Ph.D. Chemical and Biomolecular Engineering, Johns Hopkins University    GPA 3.8           
           Joint program with National Institutes of Health (NIH) 
          Advisors: Michael J. Betenbaugh and Joseph Shiloach 
May,2015 
(expected) 
         Thesis title: cellular and process engineering to improve mammalian membrane protein expression 
B.S. Chemical Engineering, Tsinghua University, China             GPA 3.3  July, 2010 
 
Professional experience 
Jan. 2011-present: pre-doctoral research fellow, NIDDK Biotechnology Core Laboratory, 
National Institutes of Health, Bethesda, MD. 
 
Research 
 10L-scale production and purification of hard-to-express membrane protein 
 * Designed and constructed vectors for inducible neurotensin receptor (NTSR1) expression in HEK293 
cells 
 * Constructed stable HEK293 cell clones for inducible NTSR1 expression 
 * Selected production clones using flow cytometry and ligand-binding assay 
 * Adapted production clones into high density serum-free suspension culture   
 * Designed and optimized NTSR1 manufacturing method  
 * Operated 10L bioreactor followed by immobilized metal ion affinity chromatography for 
manufacturing of NTSR1 
 * Determined the quality and quantity of NTSR1 product  
 * Quantitatively compared NTSR1 production from HEK293 and baculovirus-insect cell expression 
system 
 High-throughput microRNA screen for improved recombinant protein expression 





 * Fine-tuned workflow and solved technical difficulties in the automated screening procedure 
 * Screened human microRNA library with NTSR1-GFP expressing cells 
 * Proposed to combine NTSR1-GFP data with luciferase data to identify common hits improving 
protein produciton 
 * Verified the effectiveness of identified common hits (microRNAs) with other secreted and membrane 
proteins 
 * Constructed stable microRNA over-expressing cell line for enhanced phenotype 
 High-throughput whole-genome siRNA screen for improved cell growth and recombinant protein 
expression 
 * Fine-tuned workflow and solved technical difficulties for whole-genome siRNA screening 
 * Screened human whole-genome siRNA library with NTSR1-GFP expressing cells 
 * Statistically analyzed large-scale whole genome data for both NTSR1-GFP and luciferase screens 
 * Executed pathway analysis to obtain biological interpretation of the screen result 
 * Identified and validated top molecules (siRNAs) for improved cell growth and protein expression 
 * Verified the effectiveness of identified top molecules (siRNAs) with other secreted and membrane 
proteins 
 * Investigated the mechanistic explanation for improved protein overexpression 
 * Designed CRISPR array screening for construction of stable cell line knocking out identified genes  
 Transient overexpression and purification of Respiratory syncytial virus (RSV) fusion protein 
 * Investigated four expression vectors for optimal secreted expression of RSV F0 protein. 
 * Optimized transient transfection parameters and produced RSV F0 protein accordingly. 
 * Purified RSV F0 protein with immobilized metal ion affinity chromatography. 
 Rotavirus amplification in Madin-Darby canine kidney (MDCK) cells  
 * Amplified four strains of rotavirus in MA104 cells and demined rotavirus titer in cell culture lysate 
 * Adapted rotavirus to MDCK cells  
 * Determined virus titer change during adaptation using classical plaque assay and ELISA test 
Collaborative/ supervisory/ technical work 
 * Collaborated with students, postdocs, staff scientists and technicians from both domestic and 
international locations. Collaborative effort includes setting up regular meetings, transferring of cell 




editing manuscripts, etc. 
 * Served as a teaching assistant for bioseparation course (90 undergraduate students) for 2 semesters. 
Work includes delivery lectures, holding office hours to answer questions, establishing and trouble-
shooting new equipment for lab, organizing students for lab practicing, etc.  
 * Supervised two graduate students and two undergraduate students on cell culture, cell engineering, 
virus amplification, data analysis and thesis writing. 
 * In charge of preventive maintenance and calibration of analytical instruments. 
 * Maintained updated inventory of analytical instrument, lab equipment, consumables and cell lines. 
 *Searched for state-of-the-art analytical instruments for purchasing recommendations. 
 * Created bacterial and mammalian cell banks 
 
June- Sept. 2014: managerial internship at Center for Drug Evaluation (CDE), China 
Food and Drug Administration, Beijing, China. 
 * Investigated Good Review Practices (GRP) and Quality Management System(QMS)  
 * Proposed to CDE on implementing ISO 9000 QMS with Six Sigma or Lean methodologies for 
continuous improvement 
 * Led a group of interns to search, translate and compile USFDA QMS/GRP documents  
 * Interviewed and worked with consulting firms on implementing QMS/GRP in CDE 
 
October 2008- June 2010: Undergraduate research at Department of Chemical 
Engineering, Tsinghua University, Beijing, China  
 * Produced violacein through microbial fermentation, extraction and purification. 
 * Characterized and analyzed violacein product. 
 * Introduced the entire violacein synthetic pathway from Duganella sp. B2 into C. freundii to achieve 
high efficient biosynthesis of violacein. 
 * Explored possible impact factors on efficient biosynthesis of violacein by integrating the information 
on transcription/translation level of violacein biosynthesis gene cluster, fermentation characteristics and 
intracellular pH. 
 
July-Sept. 2009: summer training program at Technical University of Denmark, 
Novozymes and Nordic Sugar, Denmark 




exchange, fluid bed powder processing and filtration. 
 * Studied the bioprocess of enzyme and sugar production and inspected equipment in each section. 
 
Publications 
Xiao S, Chen YC, Betenbaugh MJ, Martin SE, Shiloach J: MiRNA screen for improved functional 
expression of  
       neurotensin receptor. Biotechnology and Bioengineering 2015. 
Xiao S, Shiloach J, Grisshammer R: Construction of recombinant HEK293 cell lines for the expression 
of the      
       neurotensin receptor NTSR1. Methods in Molecular Biology 2015, 1272:51-64. 
Xiao S, Betenbaugh MJ, Shiloach J: Engineering Cells to Improve Protein Expression. Current Opinion 
in Structural Biology. 2014 Apr 3; 26C:32-38. 
Xiao S, White JF, Betenbaugh MJ, Grisshammer R, Shiloach J: Transient and stable expression of the 
neurotensin receptor NTS1: a comparison of the baculovirus-insect cell and the T-REx-293 
expression systems. PLoS One 2013, 8:e63679. 
Jiang PX, Zhang RP, Wang HS, Xiao S, Yang C, Xing XH: Outer space mutagenesis of violacein-
producing strain by spacecraft Shenzhou-7 and screening of the mutants with high violacein 
productivity. Journal of Chemical Industry and Engineering 2010, 61(2): 461-461. 
 
Scientific meetings/ presentations 
Xiao S, Chen YC, While JF, Betenbaugh MJ, Martin SE, Grisshammer R, Shiloach J, ‘Engineering 
towards improved functional expression of neurotensin receptor’. 11th Annual Graduate Student 
Research Symposium, Bethesda, US, Jan. 2015 (poster, travel award winner) 
Xiao S, Chen YC, Betenbaugh MJ, Martin SE, Shiloach J, ‘Systems and Synthetic Biotechnology 
Platform for Characterizing and Designing HEK293 Cells’. IBC’s 10
th
 Annual Cell Line 
Development & Engineering conference, Berkeley, CA, US, Sept. 2014 (Oral) 
Xiao S, White JF, Betenbaugh MJ, Grisshammer R, Shiloach J, ‘High throughput RNA interference for 
improved functional expression of neurotensin receptor’. Cell Culture Engineering XIV, Quebec 
city, Canada, May 2014 (poster) 
Xiao S, White JF, Betenbaugh MJ, Grisshammer R, Shiloach J, ‘Transient and stable expression of the 
neurotensin receptor NTSR1: a comparison of the baculovirus-insect cell and the T-REx-293 
expression systems’. 10th Annual NIDDK Conference, Bethesda, MD, US, Apr.  2013 (poster) 
Xiao S, White JF, Betenbaugh MJ, Grisshammer R, Shiloach J, ‘Transient and stable expression of the 
neurotensin receptor NTSR1: a comparison of the baculovirus-insect cell and the T-REx-293 






Awards and Honors 
 * 2015 NIH Graduate Student Research Award (4%), National Institutes of Health, 2015 
 * 1
st
 Prize in National Competition of Chemical Process Design for College Students (2%), Chemical 
Industry and Engineering Society of China, 2009 
 * Scholarship for Scientific Innovation, Tsinghua University, 2009 
 * 1
st
 Prize in “Challenge Cup” Scientific and Technological Contest (2.5%), Tsinghua University, 2009 
 * 1
st




* Mammalian cell culture (CHO, MDCK, HEK293, Vero, MA104), insect cells (sf9), yeast and bacteria. 
* Gene and primer design, plasmid DNA cloning, bacterial transformation, transient and stable 
mammalian transfection, virus infection 
* Gene overexpression, siRNA and shRNA knock-down, CRISPR knockout 
* DNA, RNA extraction and purification, DNA and RNA gel electrophoresis, cDNA synthesis, qRT-
PCR  
* Protein expression and IMAC purification, SDS-PAGE, western blotting, ELISA, BCA, Bradford 
protein assay, ligand binding assay, other enzymatic assays (SEAP, luciferase, etc.) 
* metabolites analysis with YSI and HPLC  
* Flow cytometry, fluorescent microscopy, confocal microscopy, ImageXpress Micro. 
* Virus amplification, plaque assay, TCID50 assay, virus isolation and identification 
* Large-scale fermentation, process optimization, design of experiment 
* high-throughput RNAi and compound screening, genome scale data analysis and pathway analysis 
Personal skills 
Excellent problem-solving, organizational and interpersonal skills, able to multi-task, work 
independently or as a part of a team, good time management and prioritization skills, creative, fast-
learning, able to identify existing bottleneck and implement new protocols. 
computer 
Proficient OFFICE, ORIGIN, ENDNOTE, MATLAB, ASPEN Plus, IPA, DNASTAR, PATBASE 
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